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HEMATOPOIETIC STEM CELL TRANSPLANTATION
Advances in stem cell biology and immunology have greatly broadened the application of 
unrelated hematopoietic stem cell transplantation (HSCT) as a curative approach for patients 
suffering from a wide range of hematological disorders who lack an human leukocyte 
antigen (HLA) identical sibling donor. In non-malignant diseases the curative effect relies 
on restoration of missing stem cell function or correction of a genetic defect, congenital or 
acquired immune deficiency. In hematological malignant diseases the curative effect relies 
on both the conditioning regimen and the graft-versus-leukemia (GVL) effect.1
Currently three stem cell sources are in use: bone marrow (BM), mobilized peripheral 
blood stem cells (PBSC) and umbilical cord blood units (CBU). Every source differs 
considerably and has its advantages and disadvantages.2,3 Research described in this 
thesis focuses on HSCT using BM and PBSC only. Before intravenous infusion of the 
stem cells the patients undergo a conditioning regimen, which is either myeloablative 
or reduced intensity. It is used to treat the patients’ malignant disease and to reduce 
disease burden and, in addition, to immunosuppress the patient to allow engraftment 
of the donor immune system and/or to make space for incoming stem cells in the 
marrow. Choice of conditioning regimen is made depending on requirement of one or 
all of these functions based on donor-recipient pair characteristics.4 Subsequently, in all 
patients immunosuppression is required to achieve successful engraftment.
Transplantation of cells from donors into patients who are genetically distinct will 
lead to alloreactivity. Allografts have the potential to induce both graft-versus-host 
(GvH) and host-versus-graft (HvG) immune responses. These responses may cause 
major complications after HSCT, including graft failure, acute or chronic graft-versus-
host disease (GVHD) or lack of GVL. Acute GVHD (aGVHD) occurs when recipient 
antigen-presenting cells (APC) present ‘non-self’ antigens [(HLA molecules or minor 
histocompatibility antigens (mHags)] to donor T cells. Since professional host APCs 
are only present weeks or months after HSCT, the risk of aGVHD decreases as time 
passes. A maximum of 100 days is generally used as cut-off time point when looking 
at aGVHD. Specific target tissues in aGVHD are skin, gastrointestinal tract and liver. 
Three months after HSCT chronic GVHD (cGVHD) can develop. Mechanisms leading to 
cGVHD are largely unknown. Previous development of aGVHD is the main risk factor; 
although cGVHD can also develop without prior aGVHD. Some approach to prevent 
GVHD is required in all allografts including T cell depletion (TCD), GVHD prophylaxis and 
post transplantation immunosuppression.5 Another common cause of treatment failure 
after HSCT for malignant diseases is relapse. Relapse risk varies widely among patients 
depending on stage of disease at time of HSCT (complete remission (CR) or active 
disease). Disease relapse is thought to occur either because the disease redevelops 
from residual malignant cells after conditioning (early relapse) or due to lack of immune 
control by GVL (late relapse).6 DNA virus reactivation, opportunistic infections and 
damage to non-hematopoietic tissues also pose a serious threat of the success of HSCT.
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HSCT outcome is measured by major end points such as incidence of mortality, 
GVHD and relapse. Factors determining HSCT outcome include time from diagnosis 
until transplantation, degree of HLA matching, donor and patient characteristics, 
underlying disease, transplant composition and HSCT related treatment. In the next 
paragraphs factors relevant for the research described in this thesis will be discussed.
Unrelated donor search
The usage of unrelated donors (UD) in allogeneic HSCT has increased and is likely to 
continue to rise in the coming years.7 This demand for UDs has changed the process of 
UD searches in the past decades. If no HLA matched donor is identified in the family, a 
search in Bone Marrow Donors Worldwide (BMDW) can determine whether a potential 
suitable donor is available in the world without the need to approach all registries 
individually.8 Today the number of unrelated HSCT and CBUs registered in BMDW has 
reached over 20 million. For patients of North West (NW) European origin, shortage of 
donors is no longer the biggest constraint in unrelated HSCT. Only approximately 10% 
of NW European patients lacked a suitable donor (including HLA mismatched donors), 
whereas 30% became medically unfit for HSCT during the search process unrelated to 
donor availability.9 Decreasing time between start of the search and transplantation was 
identified as the biggest obstacle for successful HSCT.
UD selection and search process for HSCT performed at Europdonor foundation has 
been published previously10. Briefly, all patients are typed at allele level for HLA-A, -B, 
-C, -DRB1/3/4/5, -DQB1 and -DPB1. After a search request is received at Europdonor a 
search is started in BMDW. A selection of donors and/or CBUs is made which have the 
highest probability of being 10/10 HLA matched, taking into account the level of typing 
of the donors, linkage disequilibrium (LD) and the country and ethnicity of donors (if 
available). The number of donors selected per patient depends on availability of donors, 
presence of rare alleles, and urgency of the search. If possible, a higher number of 
potential donors are requested for patients with a less common HLA phenotype and/or 
high transplantation urgency. In case of a HLA class I mismatched donor, the cytotoxic 
T lymphocyte precursor (CTLp) assay is performed. The donor with no detectable 
CTLp frequency is the preferred donor. If no 9/10 HLA or higher matched donor or 6/6 
HLA matched CBU is available, HSCT with an 8/10 HLA matched donor, a haplotype 
mismatched family donor (FD), a mismatched CBU or double CBU is considered.
Access to HSCT
While unrelated HSCT is a well established potential curative therapy, there still is 
debate on which patients are better off receiving an HSCT and which patients should 
not receive one. It is methodologically difficult to evaluate the impact of HSCT relative 
to other treatment options and decide what is the optimal time point to proceed to 
HSCT.11 As a consequence of this controversy, not all patients in need of a transplant 
may receive or are offered one.9,12-18
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As stated previously, the most important limiting factor for undergoing HSCT is 
not necessarily the availability of a suitable stem cell donor, but deterioration of the 
patients’ clinical condition or death during the search process.9,15,18 However, another 
important factor which may influence the pre transplantation phase is referral bias.12,15,17 
Referring physicians may not always inform patients about HSCT as an option for 
treating their disease or do not refer patients to HSCT centers at an optimal time in 
the disease course. Late referral leads to suboptimal outcomes and fewer patients are 
able to proceed to HSCT. Therefore, physicians may be encouraged to refer a patient 
as early as possible, even if the final decision whether to transplant or not has not 
yet been made.12,15,17 Other possible barriers for receiving HSCT which may play a 
role in the pre transplantation phase include; (socio)economic factors of individual 
patients12,18 or countries,13,14 physician practice variation,16 HSCT center distribution14,19-21 
or combinations of these effects.
The role of these factors has not been studied in the Netherlands yet and they 
deserve more attention, referral bias may be a factor and poses important questions. 
Are patients who do not proceed to HSCT because of deterioration of their clinical 
condition or death during the search process referred to a HSCT center in a later 
stadium of their disease? And if so, how can we encourage physicians to refer their 
patients as soon as possible?
HLA SYSTEM
The biological role of the major histocompatibility complex (MHC) is to present 
processed antigens as peptides to T cells to provide protection against pathogens. In 
humans the MHC molecules are known as HLA. T cells survey tissue cells for the presence 
of pathogens. The T cell receptor (TCR) recognizes foreign antigens in the form of 
peptides presented by specific molecules of the HLA complex, this process is called HLA 
restriction. During T cell maturation in the thymus, TCRs are subjected to two forms of 
quality control: they must have some tendency for binding self HLA molecules (positive 
selection) because they will be required to respond to foreign peptides complexed 
with self HLA molecules in the periphery, but they must not bind to them too tightly 
(negative selection) because of the potential for autoimmune reactions.
HLA molecules are polymorphic membrane glycoproteins which are encoded by 
multiple genetic loci within the MHC. The HLA class I molecules (HLA-A, -B and -C) are 
expressed on the surface of nearly all nucleated cells, while the HLA class II molecules 
(HLA-DRB1, -DQB1 and DPB1) are expressed a more limited subset of cells, mainly on APCs. 
The human MHC is located on the short arm of chromosome 6 and is known to be the 
most polymorphic genetic region in the human genome (Figure 1). Currently the number 
of alleles of the classical HLA class I and class II loci identified has reached over 8000.22 The 
human MHC is divided into three regions. The class I region contains the classical HLA-A, -B 
and -C genes that encode the heavy chains of class I molecules. The class II region consist 
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of a number of sub regions containing A and B genes encoding α and β chains of the class 
II HLA-DR, -DQ and DP genes. The class III region does not encode HLA molecules, but 
contains a number of other genes involved in immunological processes. 
HLA matching 
The HLA system is clinically important in HSCT because HLA molecules are the main 
target antigens for the alloimmune response. Molecular HLA allele typing is routinely 
performed to provide matching in unrelated HSCT. Due to the enormous polymorphism 
of the HLA system, complete matching of donor and patient is in a large number of 
cases not possible. Advances in the immunogenomics of HLA have been made through 
examination of the alleles and antigens of large populations of transplanted donor-
recipient pairs.23 Generally, donor-recipient matching for the classical HLA loci HLA-A, -B, 
-C, -DRB1 and -DQB1 is considered as the gold-standard for donor selection.24 Additional 
HLA-DPB1 matching is favored if possible.25 However, researchers have been trying to 
identify (HLA) factors determining HSCT outcome, which has triggered discussions on 
what should be considered for donor-recipient matching in HSCT. Is matching for all 
classical HLA loci required, or are some more relevant than others?26 Is a mismatch on 
allele level better than a mismatch on antigen level?27 Currently, for instance matching 
for HLA-DQB1 is not considered obligatory by the National Marrow Donor Program 
(NMDP) and an 8/8 HLA matched donor is qualifies as sufficiently matched.28 
HLA Haplotypes
HLA genes are closely linked and the entire MHC is inherited as an HLA haplotype from 
each parent. Possible random combinations of alleles from different HLA loci on an 
HLA haplotype are enormous, but certain HLA haplotypes are found more frequently 
in some populations than expected from the Hardy-Weinberg equilibrium (random 
distribution). This phenomenon is called linkage disequilibrium (LD). Delta (D) is 
the absolute measure of LD and is defined by the difference between the observed 
haplotype frequency (HF) and the HF that would be expected from the gene frequency 
(GF) of the alleles in the haplotype in the absence of LD.29 
Knowledge about common HLA haplotypes with high LD in different populations 
may be used to our advantage during an UD search. For patients with common HLA 
haplotypes it is probably more likely to find a suitable donor within their own ethnicity 
compared to other populations.
Additional advantages of common frequent HLA haplotypes and LD have become 
apparent more recently. Petersdorf et al showed that beside HLA matching, matching 
for HLA haplotypes had an additional positive effect on HSCT outcome.30 As a result, 
the importance of non-HLA genetic variations that also map to the human MHC on 
chromosome 6 in clinical outcome is increasingly being recognized. The class III region 
of the human MHC is a densely packed region consisting of a variety on non-HLA genes 
involved in immunological processes; such as genes for complement components (C2, 
factor B, C4), heat shock protein 70 (Hsp70) and tumor necrosis factor (TNF) (Figure 1).
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Because of LD between HLA and non-HLA genes, donor-recipient pairs who are 
matched for HLA may also have a higher probability to be matched for the entire HLA 
haplotype and other genes residing between the HLA genes on the haplotype. The 
frequency of the HLA haplotype and the strength of LD may be a proxy measure of the 
probability of additional matching of non-HLA genes.
Figure 1. The human MHC complex on the short arm of chromosome 6 with HLA and non-HLA 
genes. Picture adapted form Valente et al.31
MOLECULAR BASIS OF T CELL ALLORECOGNITION
HLA class I molecules consist of a transmembrane α chain, a noncovalently associated 
light chain β2-Microglubolin and the peptide presented in the peptide binding groove 
of the α chain. The α chain contains three extracellular domains (α1, α2 and α3). The 
α1/α2 domain is a platform of eight β strands topped by 2 α helices.32 A large groove 
between the α helices provides a binding site where processed peptide of 8 to 10 
amino acid (AA) residues can bind. The majority of polymorphisms within the HLA 
class I molecule are concentrated in and around this binding groove creating a diverse 
array of potential TCR binding sites (Figure 2).32 The AA residues in the α helices are 
residues which can make direct contact with the TCR, while 6 pockets (A-F) in the  β 
sheet facilitates peptide binding determining conformation and allorecognition. TCR 
recognition of the peptide is accomplished directly by relatively few contacts with 
peptide side chains that point upwards toward the TCR. Other peptide side chains 
could be recognized indirectly by subtle conformational changes of HLA residues when 
different peptides are bound.33,34 
In HSCT, unwanted HLA-TCR interactions can profoundly affect the health of the 
recipient leading for instance to GVHD. Allorecognition of foreign HLA is complex and 
can either be direct or indirect. Direct allorecognition occurs when recipient T cells 
directly recognize donor cells expressing intact mismatched HLA molecules. Indirect 
allorecognition involves donor antigen uptake by recipient APCs. Allopeptides can be 
derived from HLA molecules or mHags that differ between donor and patient.35
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Acceptable mismatches and CTLp assay
Because of polymorphism and varied HLA phenotype distribution between ethnic 
groups it is difficult to find a 10/10 HLA matched donor for every patient in need of 
an HSCT. Some patients are transplanted with a 9/10 single HLA class I mismatched 
donor. The immunogenicity of class I mismatches may differ because some patients 
transplanted with an HLA mismatched donor have an excellent HSCT outcome whereas 
others have a poor HSCT outcome with enormous complications. It would be very 
useful to have a tool to identify which mismatches are acceptable for HSCT. In our 
center the CTLp assay is used to provide functional information on the allogenicity of 
HLA mismatches and can be applied to select among HLA mismatched donors. The 
assay measures the number of cytotoxic T cells (CTLs) in the peripheral blood able to kill 
an allogeneic target. The CTLp assay we use is a limiting dilution assay where donor cells 
are used as responder cells and patient cells as stimulator and target cells. A negative 
CTLp assay is defined as ≤1 recipient specific CTL per 106 peripheral blood lymphocytes 
(PBL).36 These CTL precursors are clinically relevant because donor-recipient pairs with 
a negative CTLp assay have statistically significant less mortality compared to donor-
recipient pairs with a positive CTLp assay.37 However, it is a difficult and time consuming 
test hence the search for a more convenient alternative.
AA sequence and physicochemical properties 
Several attempts have been made to define acceptable HLA class I mismatches for HSCT 
by identifying polymorphic regions and/or AA differences in the HLA molecules which 
Figure 2. Ribbon structure of HLA Class I molecules. A Side view of an HLA class I molecule with 
the β2-Microglubolin and three extracellular α1/α2 and α3 domains. B and C Top view of the α1/
α2 domain of an HLA class I molecule. The α1/α2 domain consist of two α helices and a β sheet 
in between. Location of high points on α helices indicated by arrows in B and C. Approximate 
footprint of a TCR indicated in B, suggesting that the TCR is aligned diagonally across the HLA/
peptide surface. Picture adapted from Bjorkman.38
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are important for allorecognition. Algorithms like HLAMatchmaker and Histocheck were 
proven not to be useful for prediction of CTL alloreactivity in HSCT.39-41 A wide array of 
AA positions and specific allele mismatches have been found to be associated with CTL 
alloreactivity and/or HSCT outcome. However, associations found in one population are 
not easily reproduced in, or translated to another population. The result is that not a single 
position or allele mismatch was consistently identified to be detrimental or favourable.42-48
Furthermore, not every AA residue might influence allorecognition in the same way. 
It may be dependent on position in the HLA molecule (α helices, β sheet or specific 
hotspots), or on physicochemical properties of the AAs of the mismatched residues 
involved. Unfortunately, up to now for HLA class I mismatching no consensus has been 
reached on a suitable algorithm predicting HSCT outcome accurately which can be used 
in donor selection. For HLA class II mismatching a recent publication shows a method 
of distinguishing permissive vs. non-permissive HLA-DPB1 mismatches for HSCT based 
on T cell epitope matching.49 However, polymorphism of HLA class I and II molecules 
are too different to benefit from this approach.
AIM AND OUTLINE OF THE THESIS
The studies described in this thesis are aimed at improving the whole spectrum of 
unrelated HSCT in order to help as many patients in need of HSCT as possible. It covers 
three different but related topics; from access to HSCT to optimizing donor search and 
selection of acceptable mismatches to improving HSCT outcome.
In chapter 2 we investigate access to HSCT in the Netherlands for children with relapsed 
acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see whether 
patients eligible for HSCT are actually offered one and what might be the reasons for 
not referring a patient. Chapter 3 describes the role frequent HLA haplotypes may 
play in donor search and what the effect may be on HSCT outcome. In chapter 4 we 
propose an algorithm constructed by logistic regression analysis for prediction of CTL 
alloreactivity. It is based on number, position and physicochemical compatibility of AA 
differences in class I HLA molecules. This algorithm may be effective in identifying 
mismatched donors acceptable for HSCT. Before we can use this algorithm clinical 
validation is needed. Therefore we tried to translate the use of this algorithm from 
in vitro CTLp assay to in vivo HSCT. Studies aiming at the prediction of outcome of HSCT 
are described in chapter 5.  Finally in chapter 6 we tested an algorithm developed by the 
transplantation group in Cambridge, which focused on electrostatic and hydrophobic 
properties of AA differences in class I HLA molecules, on the population we used for 
development of our own algorithm. Their algorithm was developed for prediction of 
humoral alloreactivity in organ transplantation and we wondered what could be the 
additional impact of a similar approach on cellular alloreactivity in HSCT.
General introduction
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ABSTRACT
In order to investigate whether all patients in need of an allogeneic hematopoietic stem 
cell transplantation (HSCT) are offered one, we retrospectively investigated the policy 
for all children diagnosed with myelodysplastic syndrome (MDS) (n=90) or relapsed 
acute myeloid leukemia (AML) (n=75) between 1998 and 2008. These children are 
registered at diagnosis and treated according to protocols of the Dutch Childhood 
Oncology Group (DCOG), which provides accurate disease incidence data and protocol 
indicated appropriateness for HSCT. For 48 (30%) patients a family donor (FD) was 
identified, for 90 (57%) patients an unrelated donor (UD) search was performed and for 
21 (13%) patients no UD search was initiated. Reasons for not initiating an UD search 
include: Progressive disease (n=10), conserve quality of life (n=1), stable disease (n=3), 
immunosuppressive therapy (n=2), patient died (n=3), patient lives abroad (n=1) and 
second relapse (n=1). On the basis of the time interval between date of diagnosis and 
date of death/last follow up, for eight (5%) patients it may be questioned why an UD 
search was not performed. The fact that 95% of all children are given the option of an 
allogeneic HSCT is encouraging and reasons not to transplant seem fair in most cases.
18
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INTRODUCTION
In the Netherlands, all children with malignancies are registered at diagnosis and 
treated according to protocols of the Dutch Childhood Oncology Group (DCOG).50 
Children with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) 
in first relapse are considered candidates for allogeneic hematopoietic stem cell 
transplantation (HSCT) as described in the DCOG treatment protocols.51,52 This provides 
a unique opportunity to investigate whether allogeneic HSCT is offered as a therapy 
to all children in the Netherlands, as accurate disease incidence data and protocol 
indicated appropriateness for HSCT are available.
Although allogeneic HSCT is considered a curative therapy for several childhood 
hematopoietic malignant diseases,1 the presumption exists that not all patients in need of 
an allogeneic HSCT are offered one.12,15,18,53,54 Despite the use of treatment protocols and 
specific guidelines for allogeneic HSCT there may be a number of reasons for patients not 
receiving allogeneic HSCT. First of all, the most important requirement for a successful 
allogeneic HSCT is the availability of a suitable donor, ideally an HLA identical family 
donor (FD). Unfortunately, for approximately 25% of the patients such a donor is available. 
Consequently, most patients have to rely on other donor types, including non-identical 
FDs, unrelated donors (UD) and cord blood units (CBU). For approximately 80-90% of 
(North-West European) patients who lack an identical sibling donor an unrelated donor 
is identified.9,10 Furthermore, it has been shown that of all patients for whom an UD search 
was initiated a significant group is not transplanted.9,18 Not the duration of the search 
process itself or the availability of a suitable donor, but the worsening clinical condition 
of the patient during the search process is the main cause for this low HSCT rate.9,18 
Other barriers for access to an allogeneic HSCT include physician characteristics or 
preferences,16,55 socioeconomic factors and access to the healthcare system or HSCT 
centers13,15,18-21 and type of hospital or HSCT center.55,56 Potential causes for lack of 
access to allogeneic HSCT may be due to discussion on the efficiency of allogeneic 
HSCT versus chemotherapy or autologous HSCT and whether to transplant in first or 
second complete remission (CR).57-69 Lack of consensus on the best indication(s) for 
allogeneic HSCT remains a problem since it is methodologically difficult to evaluate the 
advantage of allogeneic HSCT over chemotherapy or autologous HSCT.70,71
The main reason for this debate are the high treatment related mortality (TRM),58,63,72,73 
adverse late effects and worse quality of life (QOL) associated with allogeneic HSCT.60,74,75 
Especially allogeneic HSCT with an UD remains somewhat controversial for a large part 
of patients and is therefore advised to be performed in the context of clinical trials.57 
For certain high risk disease patients or patients whose disease relapsed and who lack 
an identical FD, allogeneic HSCT with an UD is indicated.69,76-78
In all these studies, only patients for whom an UD search was performed were 
included. As a consequence, a large number of patients who are appropriate candidates 
for an allogeneic HSCT might have been omitted from the study population. In addition, 
hypothetical and/or incomplete disease incidence data was used.
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The aim of the present study is to investigate whether appropriate pediatric patients 
in the Netherlands are given the opportunity of an allogeneic HSCT and if not, to 
identify possible reasons and solutions.
PATIENTS AND METHODS
Dutch Childhood Oncology Group (DCOG)
The DCOG was founded in 2002 and evolved from the Working group Leukemia in 
Children which was established in 1972. The activities of the DCOG are more extensive 
than those of the Working group and cover not only children with leukemia and 
lymphoma, but focus on all cancers in pediatric patients. The DCOG is a nationwide 
partnership where pediatric oncologists and other professionals in this area work closely 
together, which aims to provide the best available treatment to the child and his parents. 
Protocols and HSCT indication
All children (<18 years of age) were treated according to DCOG treatment protocols. 
The MDS protocols are developed in collaboration with the European Working Group 
of MDS and juvenile myelomonocytic leukemia (JMML) in Childhood (EWOG-MDS). 
These studies are conducted in accordance with the Declaration of Helsinki and all 
patients’ caretakers signed written informed consent forms before enrolment.
EWOG-MDS-199879: Allogeneic HSCT is the treatment of choice for children with all 
disease classification types if a compatible FD or UD is available.
Relapsed AML 2001/01 (online access via clinicaltrials.gov): Patients in CR after two 
courses of reinduction chemotherapy are eligible for allogeneic HSCT. For both low risk 
[= late first relapse (≥ one year from initial diagnosis)] and high risk disease [= early first 
relapse (< one year from initial diagnosis), multiple relapse or refractory disease], HSCT 
with a compatible FD or UD is indicated. Irrespective of disease risk, an allogeneic HSCT 
should be avoided within 12 months after a previous allogeneic HSCT.
EWOG-MDS-2006 (online access via clinicaltrials.gov): Therapy options for MDS 
depend on disease classification type and are therefore diverse. However, in most cases 
the only potential curative therapy is allogeneic HSCT with either a compatible FD 
or UD. Patients with refractory cytopenia (RC) or refractory anemia (RA) have several 
options before the need for an allogeneic HSCT, including ‘wait and see’ approach, 
transfusion therapy and immunosuppressive therapy (IST). Patients with high risk MDS 
(RAEB and RAEB-T) and JMML should be transplanted as soon as possible.
Study population
All children in the Netherlands diagnosed with primary MDS (n = 90) or AML in first 
relapse (n = 75) between 1998 and 2008 were included in this retrospective study. 
Six patients were excluded from analysis, as they were rightly excluded from HSCT 
according to the protocol or advice from the protocol chairs. Two of these patients 
were not eligible for protocol treatment according to exclusion criteria described in the 
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protocols; one MDS patient had Down syndrome and one relapsed AML patient was 
diagnosed with FAB type M3. Four AML patients relapsed within 12 months after they 
were transplanted in first CR and therefore were not considered appropriate candidates 
for a second allogeneic HSCT. Consequently, 159 patients were analyzed.
Statistics
To characterize the patients who did not have access to allogeneic HSCT, we divided the 
study population into three patient groups; patients who had a FD; patients for whom 
an UD search were performed and patients for whom no UD search were performed.
We investigated gender (male/female), diagnosis (MDS/relapsed AML), age at 
diagnosis (continuous), year of diagnosis (continuous), being alive at last follow up 
(yes/no) and cause of death (discrete) for differences between the three patient groups. 
Differences in discrete variables are examined with Pearson’s Chi Square test or Fisher 
Exact test and differences in variables with the Kruskal-Wallis test or Mann Whitney test.
Furthermore, we looked into the reasons for not performing an UD search with 
the patients’ corresponding survival interval to determine if the reasons could be 
considered questionable or not. For MDS patients the variables ‘survival interval’ and 
‘HSCT interval’ were defined as the number of days from diagnosis until death/last 
follow up and HSCT, respectively. For relapsed AML patients the variables ‘survival 
interval’ and ‘HSCT interval’ were defined as the number of days from diagnosis of first 
relapse until death/last follow up and HSCT, respectively. Relapse interval was defined 
as the number of days from diagnosis of AML to diagnosis of first relapse of the disease.
Two sided p-values ≤ .050 were considered statistically significant and all analyses 
were performed using SPSS 17.0 for Windows (IBM).
RESULTS
The study population consists of 159 children; 89 MDS patients and 70 patients with 
relapsed AML. For 48 (30%) patients a FD was identified (including non-identical FD), 
for 90 (57%) patients an UD search was performed and for 21 (13%) patients no UD 
search was initiated (Figure 1).
Patient and HSCT characteristics are shown in Table 1. There are no differences in sex, 
diagnosis, year of diagnosis, relapse interval, being alive at last follow up and cause of 
death between the three patient groups. Patients for whom no UD search was performed 
are on average younger at diagnosis than patients with a FD or patients for whom an UD 
search was performed (2.4 vs. 8.5 years; p-value = .018). Of the patients with a FD 85% 
(n = 41) received a HSCT and of the patients for whom an UD search was performed 74 
(82%) received a HSCT. The majority of patients were transplanted with an identical FD 
[n = 31 (76%)] or a 10/10 matched unrelated donor (MUD) [n = 53 (72%)].
Seventy-eight (68%) patients received a bone marrow graft. For patients transplanted 
with a FD the median interval from diagnosis to HSCT was 116 days and 75% was 
transplanted within 176 days. For patients transplanted with an UD the median interval 
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Figure 1. Study population
from diagnosis to HSCT was 139 days and 75% was transplanted within 185 days. Since 
patients with a FD and patients for whom an UD search was performed will have to be 
alive up to that point they on average live longer than patients without UD search (630 
vs. 511 vs. 107 days, respectively; p-value = .000).
The 21 patients for whom no UD search was initiated were divided into patients with 
and without access to allogeneic HSCT according to the reasons not to perform an UD 
search, which are listed in Table 2.
For relapsed AML patients the predominant reason not to perform an UD search 
was death in progressive disease [n = 10 (6.3%)]. Four of them died on average one 
month after diagnosis of the first relapse (median (range) = 31 (7-49) days). The other 
six patients lived long enough after first relapse (median (range) = 103 (63-123) days) 
to have had an UD search performed for them. The fact that these patients were not in 
CR should not have prevented an UD search.
Three patients died within 41 days after diagnosis of MDS. The possibility of 
allogeneic HSCT was discussed with all three patients; however they died before an UD 
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2Table 1. Patient and HSCT characteristics
No FD
no UD search
n=21
No FD
yes UD search
n=90
FD
n=48
Total
n=159 p-value
Male n (%)* 14 (66.7) 52 (57.8) 31 (64.6) 97 (61.0) .626
Diagnosis MDS, n (%)* 10 (47.6) 54 (60.0) 25 (52.1) 89 (56.0) .477
Diagnosis (year),
median (range)#
2004
(1998-2008)
2004
(1998-2008)
2003
(1998-2008)
2004
(1998-2008)
.363
Age at diagnosis,
median (range)#
2.4 (0.1-16.6) 8.5 (0.2-16.9) 8.5 (0.3-17.6) 8.0 (0.1-17.6) .018
Relapse interval (days),
median (range)#
219 (94-348) 289 (29-1064) 252 (29-758) 265 (29-1064) .130
Survival interval (days),
median (range)#
107 (5-2331) 511 (24-3317) 630 (21-3614) 468 (5-3614) .000
Alive at last follow up, n (%)* 6 (28.6) 44 (48.9) 26 (54.2) 76 (47.8) .140
Cause of death, n (%)+ .129
   Progressive disease 12 (80.0) 20 (43.5) 13 (59.1) 45 (54.2)
   Relapse 1 (6.7) 8 (17.4) 6 (27.3) 15 (18.1)
   Infection 0 9 (19.6) 1 (4.5) 10 (12.0)
   GVHD 0 3 (6.5) 1 (4.5) 4 (4.8)
   Other HSCT related 0 4 (8.7) 1 (4.5) 5 (6.0)
   Other 2 (13.3) 2 (4.3) 0 4 (4.8)
Received HSCT, n (%)* 0 74 (82.2) 41 (85.4) 115 (72.3) .000$
HSCT interval (days), n (%)^ NA 139 (69-1042) 116 (22-593) 130 (22-1042) .073$
Donor type, n (%)* NA .644$
   Identical FD or 10/10 UD 53 (71.6) 31 (75.6) 84 (73.0)
   Non-identical FD or UD 21 (28.4) 10 (24.4) 31 (27.0)
Graft type, n (%)+ NA .226$
   BM 53 (71.6) 25 (61.0) 78 (67.8)
   PBSC 13 (17.6) 12 (29.3) 25 (21.7)
   CBU 8 (10.8) 3 (7.3) 11 (9.6)
   Unknown 0 1 (2.4) 1 (0.9)
*Pearson’s Chi Square test; #Kruskal-Wallis Test; +Fisher Exact test; ^Mann Whitney U test; $Compared 
No FD/UD search vs. FD group. FD: family donor; UD: unrelated donor; MDS: myelodysplastic syndrome; 
GVHD: graft versus host disease; HSCT: hematopoietic stem cell transplantation; BM: bone marrow; 
PBSC: peripheral blood stem cells; CBU: cord blood unit; NA: not applicable
Access to unrelated HSCT
search was initiated. For five patients, diagnosed with MDS-RC or -RA, other treatment 
options were chosen instead of allogeneic HSCT in accordance with the treatment 
protocol. Three patients had stable disease and the ‘wait-and-see’ approach was 
applied, the other two were treated with IST.
Finally, one relapsed AML patient had a second relapse before an UD search was 
performed, however the interval between first and second relapse was long enough to 
initiate an UD search (73 days). Altogether, for eight (5%) patients it is questionable that 
an UD search was not performed. 
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Table 2. No UD search for patients without FD
n (%)
Survival interval (days)
median (range)
Alive
n
Fair reason
Died from progressive disease on average 31 days after 
diagnosis of relapse
4 (2.5) 31 (7-49) 0
Conserve quality of life* 1 (0.6) 1330 0
Stable disease and still alive 3 (1.9) 1115 (404-1547) 3
Immunosuppressive therapy and still alive 2 (1.3) 266 (202-329) 2
Died on average 23 days after diagnosis 3 (1.9) 23 (5-41) 0
Subtotal 13 (7.5) 5
Questionable reason; should have had access to HSCT
Patient lives abroad 1 (0.6) 2331 1
Died from progressive disease but lived on average 103 
days after diagnosis of relapse
6 (3.8) 103 (63-123) 0
Second relapse, interval between first and second relapse 
was 73 days
1 (0.6) 92 0
Subtotal 8 (5.0) 1
Total 21 (13.2) 6
*Patient also had tetraplegia; UD: unrelated donor; FD: family donor; CR: complete remission; HSCT: 
hematopoietic stem cell transplantation.
DISCUSSION
This study investigated access to allogeneic HSCT for children in the Netherlands. The 
results show that in this population with poor prognosis for most patients the indication 
for allogeneic HSCT is clear.
For eight (5%) patients it is questionable that an UD search was not performed. 
Poor clinical condition may have been the reason to omit the search, and one could 
argue what is the optimal moment to initiate an UD search, but strictly looking at the 
time intervals regardless of whatever happened to the patient in a later time point 
these eight patients should have had access to an allogeneic HSCT. The fact that most 
children are given an allogeneic HSCT is encouraging and reasons not to transplant 
seem fair in most cases.
These Dutch results are in contrast with HSCT rates reported in the USA, where 
patients who were diagnosed with diseases potentially treatable with allogeneic HSCT, 
only an estimated 17% would theoretically undergo one.18 Probably this percentage 
is even lower since some of these patients may not need a HSCT and can be treated 
with other therapies. However, there are some major differences with our study. First, 
the American study included both pediatric and adult patients with a wide variety of 
diseases while we only included children with MDS and relapsed AML. Second, in the 
USA approximately 11% of the children and 15% of the adults were uninsured and 
therefore did not have full access to health care and allogeneic HSCT whereas in the 
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Netherlands everyone is required to have health insurance. Third, the probabilities of 
receiving an allogeneic HSCT reported in the American paper are partly speculative 
because of incomplete disease incidence data and the assumption of universal donor 
availability.
Furthermore, the Netherlands is a small country and all Dutch children with 
malignancies are treated according to DCOG protocols leaving less room for discussion 
on which therapy would be most effective. Also because these are pediatric patients 
clinicians may be more inclined to follow protocol. Together this may result in a higher 
HSCT rate.
In contrast to the role of allogeneic HSCT in patients with MDS, where there is 
only no consensus on using an AML-like induction before allogeneic HSCT,80-82 the 
indication for allogeneic HSCT is less clear in patients with primary AML and acute 
lymphoblastic leukemia (ALL). The usage of allogeneic HSCT in those patients is limited 
by consideration of the risk-benefit ratio, especially because allogeneic HSCT implies 
a significant risk for treatment related mortality (TRM). Furthermore, the response rate 
to chemotherapy in children with AML in first CR and especially in children with ALL in 
first CR is reasonable to excellent.61 The influence of physician preferences in following 
protocol treatment or choosing allogeneic HSCT over other less aggressive therapies 
in some cases remains unknown. Recently a trend towards reduced TRM73,83 and a 
decreased incidence of aGVHD84 after allogeneic HSCT was seen. This may indicate that 
the efficiency of HSCT is improving over time which should motivate the development 
of new treatment protocols by which physicians are encouraged to refer patients in 
early stages of their high risk disease to experienced HSCT centers for consultation.
Furthermore, non-identical UD85,86 or cord blood units (CBU)87 may be included 
more often as potential donor options in current protocols based on the encouraging 
results reported so far. Therefore, the lack of an identical FD or a 10/10 MUD should 
not discourage referral and/or delay the use of HSCT when indicated. Moreover, the 
main advantage of using a CBU compared to an UD is the shorter search interval and 
faster availability.88 So in cases where the unrelated donor search might take too long 
or the patient is at high risk of relapsing, transplantation of a CBU might decrease the 
probability of deterioration of the patients’ clinical condition.
In conclusion, the HSCT rate in the Netherlands for children diagnosed with primary 
MDS or relapsed AML is relatively high and due to recent developments it may even 
increase in the future as predicted by the European Group for Blood and Marrow 
Transplantation (EBMT).13 Whether this holds true for other malignancies or adult 
patients remains to be determined and is the subject of future studies.
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ABSTRACT
The MHC region on chromosome 6 contains next to the HLA genes a large number of 
non-HLA genes. Matching for HLA in unrelated hematopoietic stem cell transplantation 
(HSCT) does not necessarily mean that these non-HLA genes are matched too. We 
selected 348 Northwest European patients transplanted with an HLA-A, -B, -C, -DRB1, 
-DQB1 matched unrelated donor (MUD) between 1987 and 2008. Patients’ haplotypes 
were identified via descend. We were unable to determine the haplotypes of the donor; 
therefore we used frequent haplotypes (FH) in high linkage disequilibrium (LD) as a proxy 
for haplotype matching. Presence of a FH in a patient positively affected the probability 
and speed of identifying a MUD. Competing risk survival analysis showed that patients 
with 1 or 2 FH have a statistically significant decreased probability of developing ≥ grade 
II acute graft-versus-host-disease (aGVHD) without increased risk of relapse compared 
to patients without FH [HR (95% CI): 0.53 (0.31 – 0.91)]. This association was strongest 
for those FH with the highest LD between both HLA-A and -C or -B and HLA-C or -B 
and -DRB1 [HR (95% CI): 0.49 (0.26 – 0.92)]. These results extend evidence that non-HLA 
allele coding regions have a significant impact on development of ≥ grade II aGVHD. We 
conclude that there is more to successful HSCT than matching for HLA genes.
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Acute graft-versus-host-disease (aGVHD) is a major cause of mortality following unrelated 
hematopoietic stem cell transplantation (HSCT). Even in patients transplanted with a 
10/10 allele level typed HLA matched unrelated donor (UD) the incidence of aGVHD 
may still be significant.24 This indicates that not only classical HLA antigen mismatches 
are responsible for the development of aGVHD. The MHC region on chromosome 6 is 
one of the most densely gene-packed segments of the human genome and contains 
a large number of non-HLA genes which spread across the entire class II, class III, and 
class I segments.89 In 10/10 HLA matched unrelated donor-recipient pairs there is no 
certainty that these non-HLA genes are matched too, because these matched pairs do 
not necessarily share the same haplotypes. The biological impact of HLA haplotype 
matching for HSCT has not been explored as extensively as that of matching for HLA 
alleles or loci. Matching for the HLA-B,-C and HLA-DR,-DQ haplotype blocks,90 and more 
recently, matching for HLA-A,-B,-DR haplotypes30 within 10/10 HLA matched unrelated 
donor-recipient pairs is associated with less post transplantation complications. 
Furthermore, Japanese patients having one of three most frequent haplotypes (FH) were 
found to have differential risk of developing aGVHD. It appeared that the genetic factor 
of specific haplotypes are associated with either increased or decreased risk of aGVHD.48
The role of some of these non-HLA genes have been studied (reviewed91-95): single 
nucleotide polymorphisms (SNPs) and or microsatellites (Msats) within cytokine 
(-receptor) genes and other non-HLA encoded genes, including those of the innate 
immune system, may indeed influence HSCT outcome.96-102 Genes in the tumor necrosis 
factor (TNF) block, MHC class I chain-related gene A/B (MICA/B) and Msat markers are 
of specific interest because they are in linkage disequilibrium (LD) with the classical HLA 
genes and could be inherited together as one genetic unit.98-100,103-106
The presence of FH in patients also affects the probability and speed of identifying 
a matched UD.107-113 It is essential to know the HLA distribution of each population at 
an allelic level in order to define whether a patient has a high or low probability to find 
a matched donor.112 Our group has previously shown that 30% of Northwest European 
patients became medically unfit during the search process and therefore did not receive 
a HSCT (which was unrelated to donor availability). Search time was identified as the 
most crucial factor in the UD search.9
The aim of this study was therefore to identify the most frequent 5 locus allele level 
typed HLA haplotypes in the Dutch population and to elucidate the effect of frequency and 
LD of the patients’ HLA haplotypes on donor search and clinical outcome of unrelated HSCT.
HLA haplotypes, UD search and HSCT
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PATIENTS AND METHODS
HLA genotyping, HLA-haplotypes and linkage disequilibrium
All donors and patients were typed at allele level for HLA-A, -B, -C, -DRB1, -DQB1 
using polymerase chain reaction sequence specific primer (PCR-SSP) and sequence 
based typing (SBT). Patients transplanted before 1996 and their donors were typed at 
allele level retrospectively. Because we were unable to determine the haplotypes of the 
donor, we used FH in high LD as a proxy for haplotype matching. Patients were divided 
into three groups; patients with two FH, patients with one FH and patients with no 
FH. Frequent 5 locus HLA-haplotypes were defined as haplotypes which occur with a 
frequency of >1% in the Dutch population (Table 1). 
Maximum-likelihood haplotype frequencies were estimated using an expectation-
maximization (EM) algorithm114 in 975 high resolution HLA typed Dutch leukemia patients. 
We also tested if the genotypes in this sample were present in the expected Hardy-
Weinberg proportions. The classical LD coefficient measuring deviation from random 
association between alleles at different loci is Delta (D).29 D is the absolute measure of LD; 
it is defined by the difference between the observed haplotype frequency (HF) and the HF 
that would be expected from the genotype frequency (GF) of the alleles in the haplotype, 
in the absence of LD. We calculated the D for the 5 locus haplotypes and also for all 
possible 2 locus haplotypes. These analyses were performed using the Pypop program.115
Donor search
UD search data were collected from the search database and the patients’ charts at 
Europdonor Foundation. Start date of the search was defined as the date a patient was 
registered for an UD search at Europdonor Foundation. Each search was individually 
reviewed; there are no fixed time scales in which a search has to be completed. The first 
donor tested and considered to be acceptable for HSCT was defined as an ‘acceptable 
donor’, these included 9/10 HLA mismatched and 10/10 HLA matched donors (HLA-A, 
-B, -C, -DRB1, -DQB1). For 29 (7%) patients the search successfully continued for a 10/10 
HLA matched donor. Therefore we made a distinction between dates an ‘acceptable 
donor’ or a 10/10 HLA matched donor was found and performed the analysis on these 
two groups separately.
Patient population
For this study we have used two different cohorts; one to investigate the impact of FH 
on the UD search (UD search analysis), and one to investigate the impact of FH on HSCT 
outcome (transplantation analysis). 
UD searches performed at Europdonor Foundation between 1987 and 2008 for 
Northwest European patients, both pediatric and adult, treated at Leiden university 
medical center (LUMC) were selected (n=580) for the UD search analysis. For 492 patients 
haplotypes could be derived by descent. Forty patients eventually underwent autologous 
transplantation and 7 patients were transplanted with a cord blood unit; these patients 
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3were excluded from the study (n=47). Patients for whom intention for treatment was 
revoked for reasons not related to the search process were excluded from the study as 
well (n=44). Reasons included: transferal to a different transplant center (n=3), indication 
for HSCT changed (n=18), different therapy was chosen (n=4), withdrawal by the patient 
(n=8) and patient not reaching complete remission (CR) during the search (n=11). Finally, 
8 patients were excluded from the study because one or more HLA loci, other than DPB1, 
were not typed. In 5 patients the C locus was not typed, in 1 patient the DQ locus was not 
typed and in 2 patients both C and DQ loci were not typed. The remaining 393 patients 
formed the study population, both pediatric and adult. The excluded cohort was not 
statistically significant different from the selected cohort (data not shown). Patient, search 
and HSCT characteristics of the UD search analysis are listed in Table 2.
To study HSCT outcome we only selected patients who had been transplanted with 
a 10/10 HLA matched UD. Because not all searches resulted in a HSCT we contacted 
two other transplant centers in the Netherlands [(Erasmus medical center (MC) and 
university medical center Utrecht (UMCU)] and included their patients as well to reach 
sufficient numbers. The selected cohort for the transplantation analysis consists of 348 
Northwest European patients, both pediatric and adult. Patients had known haplotypes 
derived from pedigree typing and were transplanted with a 10/10 HLA-A, -B, -C, 
-DRB1, -DQB1 matched UD. The patients were treated at three Dutch HSCT centers 
(LUMC, Erasmus MC and UMCU) and UD originated from national or international 
donor registries. Clinical patient information was made available by the HOVON Data 
Center from the EBMT (European group for Blood and Marrow Transplantation) patient 
database. Patient, donor and transplantation characteristics of the transplantation 
analysis are listed in Table 3.
Endpoints and competing risks
Primary endpoint for the UD search analysis was the conclusion that no ‘acceptable donor’ 
was found (9/10 HLA mismatched or 10/10 HLA matched). Patients were censored at the 
date a donor was found. Death or deterioration of the clinical condition before a donor 
was found was considered to be a competing risk. Primary endpoint for the transplantation 
analysis was the incidence of ≥ grade II aGVHD. Peak severity of aGVHD after HSCT defined 
according to grade (no (n=172), I (n=85), II (n=41), III (n=13) or IV (n=7)) was available for 
322 patients. The number of patients with grade III and IV (n=20) was too small to perform 
a meaningful analysis. Patients were censored at date of DLI, relapse or second HSCT within 
100 days after HSCT and also at 100 days after HSCT. Death without ≥ grade II aGVHD 
within 100 days after HSCT was treated as a competing risk. 
Secondary outcomes in the transplantation analysis were mortality and relapse 
incidence. For 347 patients cause of death was available, for the relapse analysis only 
patients with malignant diseases (n=290) were included. Patients were censored at date 
of DLI or second HSCT and those who survived were censored at time of last contact. 
Looking at relapse, death without relapse was defined as competing risk. 
HLA haplotypes, UD search and HSCT
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Statistical analysis
We investigated incidence of not finding a 9/10 HLA mismatched or 10/10 HLA matched 
UD (UD search analysis) and the incidence of ≥ grade II aGVHD, relapse and mortality 
(transplantation analysis) in relation to the number of FH of the patient. FH were 
categorized into three groups based on LD between the HLA-A and -C or -B loci, the 
HLA-C or -B and -DRB1 loci or both parts and also investigated the association with the 
three different HSCT endpoints. In all analyses the group without FH was set as reference.
Differences in patient-, search-, donor- and transplantation related characteristics 
between 0, 1 or 2 FH were examined with Pearson’s Chi Square test or Fishers’ exact test 
for discrete variables and Kruskal-Wallis test for continuous variables. Hazard ratios (HR), 
95% confidence intervals (95% CI) and p-values were obtained using the proportional 
hazards model for the subdistribution of competing risks of Fine and Gray116 to quantify 
the influence of FH on the UD search results and the different HSCT endpoints. 
Patient-, search-, donor- and transplantation related characteristics that were 
associated with both number of FH and UD search results or transplantation endpoints 
were considered as potential confounding variables in our datasets. These were 
evaluated for each endpoint separately and identified as confounding variables when 
including them in the model (one by one), the crude association (β estimate) changed 
by >10%. For UD search models none of the variables were identified to confound 
the association. For ≥ grade II aGVHD models patient age (continuous), Campath use 
(y/n) and conditioning (myeloablative/reduced intensity) were identified. For mortality 
models donor age (continuous), HSCT year (continuous), ABO match (y/n), CMV match 
(negative donor to positive patient), disease type (myeloid/lymphoid malignancy/non-
malignant), T cell depletion (TCD) of the graft (y/n), Campath use (y/n), disease status 
at HSCT (first complete remission or chronic phase and non-malignant/other) and 
conditioning (myeloablative/reduced intensity) were identified. 
For relapse models gender match (female donor to male patient/other), CMV match 
(negative donor to positive patient), disease type (myeloid/lymphoid malignancy/non-
malignant), ATG use (y/n), Ciclosporin use (y/n), Campath use (y/n), donor age (continuous) 
and conditioning type (myeloablative/reduced intensity) were identified. All identified 
confounding variables were included in the multivariate models to adjust for confounding.
Two sided p-values ≤ .050 were considered statistically significant. Statistical 
analysis was performed using SPSS 19.0 for Windows (IBM) and the CMPRSK package 
in R version 2.14.1 (open source). 
RESULTS
The most frequent 5 locus allele level typed HLA haplotypes found in the Dutch 
population are represented in Table 1. These frequencies were comparable to other 
Northwest European populations and the genotypes in the sample showed no evidence 
of significant deviation from Hardy Weinberg equilibrium. 
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In the UD search cohort, patients with or without FH were similar with regard to gender, 
age, diagnosis, search period, urgent searches and reasons for not reaching transplantation 
(Table 2). Of the 393 UD searches evaluated 311 (79%) were successful, either a 9/10 HLA 
mismatched or 10/10 HLA matched donor was found. For 82 (21%) patients the UD search 
was not successful; for 56 (14%) patients no donor was found and 26 (7%) patients died 
before a donor was found or because of deterioration of their clinical condition during the 
search. Of 393 patients 148 (38%) had 1 or 2 FH. For those patients a donor was found more 
often in a shorter time period compared to patients without FH. As a consequence, patients 
with 1 or 2 FH were transplanted more often (Table 2). Cumulative incidence curves show 
that in both groups (acceptable and 10/10 matched donors) for the patients with 2 FH 
always a donor was found (indicating the flat line); this is after correction for competing 
risks (deterioration of the patients’ condition or death). For patients with 1 FH there still is 
increased success in finding an acceptable donor; however the effect on finding a 10/10 
matched donor is less strong. As expected, for the group of patients without FH worse 
probability of finding a suitable donor are shown (Table 2 and Figure 1).
Table 2. Patient/search/HSCT characteristics (UD search analysis)
No FH
n=245
1 FH
n=118
2 FH
n=30
Total
n=393 p value
Pediatric patients, n (%)* 128 (52) 62 (53) 16 (53) 206 (52) .993
Male, n (%)* 146 (60) 83 (70) 18 (60) 247 (63) .132
Malignant disease, n (%)* 203 (83) 96 (81) 23 (77) 322 (82) .694
Urgent search, n (%)* 148 (60) 77 (65) 17 (57) 242 (62) .571
Search initiated <1996, n (%)* 47 (19) 30 (25) 9 (30) 86 (22) .216
Acceptable donor (9/10 mismatched + 10/10 matched)* .000
   donor found, n (%) 179 (73) 105 (89) 27 (90) 311 (79)
   no donor found, n (%) 50 (20) 6 (5) 0 (0) 56 (14)
   deterioration condition/died during search, n (%)^ 16 (7) 7 (6) 3 (10) 26 (7)
   median (range) search time (days)#
57  
(12 – 937)
43  
(13 – 789)
35  
(15 – 341)
49  
(12 – 937)
.000
Matched donor (10/10 matched)* .000
   donor found, n (%) 82 (34) 81 (69) 27 (90) 190 (48)
   no donor found, n (%) 121 (49) 26 (22) 0 (0) 147 (37)
   deterioration condition/died during search, n (%)^ 42 (17) 11 (9) 3 (10) 56 (14)
   median (range) search time (days)#
59  
(12 – 937)
52  
(13 – 789)
35  
(15 – 341)
56  
(12 – 937)
.003
No HSCT, n (%)* 108 (44) 31 (26) 9 (30) 148 (38) .003
Reason no HSCT (other than no donor), n (%)+ .878
   patient died 29 (47) 9 (36) 4 (44) 40 (44)
   no CR 12 (21) 4 (16) 2 (22) 18 (20)
   patient relapsed 9 (16) 7 (28) 2 (22) 18 (20)
   deterioration of patients condition 10 (17) 5 (20) 1 (11) 16 (17)
FH: frequent haplotype; * Pearson’s Chi Square test; #Kruskal-Wallis test; +Fisher’s exact test. ^ Deterioration 
condition/death was treated as competing risk for finding a donor. All days are calendar days.
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3Looking at the transplantation cohort, patients with and without FH were statistically 
significant dissimilar only with regard to donor age at HSCT. Patients with 1 or 2 FH 
generally have more potential donors to choose from compared to patients without FH, 
therefore the younger donors are selected for HSCT more often (Table 3). Competing 
risk survival analysis, after correction for confounding variables, showed that patients 
with one or two FH had a statistically significant decreased probability of developing ≥ 
grade II aGVHD without an increased risk of relapse compared to patients without FH 
[HR (95% CI): 0.53 (0.31 – 0.91)] (Figure 2 and Table 4). This association was strongest 
looking at the FH with the highest LD between both HLA-A and -C or -B (and HLA-C or 
-B and -DRB1 [HR (95% CI): 0.49 (0.26 – 0.92)] (Figure 3 and Table 4). We did not observe 
an effect on incidence of mortality in any analyses performed (Figure 2 and 3, Table 4).
DISCUSSION
Our UD search results as well as results published by Pedron et al.110 demonstrate that 
at time of UD search initiation, knowledge of frequent haplotypes in our own but also 
other countries may be used to develop strategies to optimize UD searches and help 
physicians to organize patient care strategies. HLA GF and/or HF can be used for the 
estimation of the probability that a haplotypically identical UD for an individual patient 
can be found.117 So, if there are multiple 10/10 HLA matched UD available for a certain 
patient, the search coordinator might want to look at registries with similar haplotype 
distribution to the patient, increasing the likelihood of haplotype matching on top of 
HLA matching. Furthermore, for patients with less frequent HLA gene combinations of 
Figure 1. Cumulative incidence of no suitable donor found searching for A acceptable donors 
(9/10 HLA mismatched and 10/10 HLA matched UD) and B 10/10 HLA matched UD for patients 
with no, 1 or 2 frequent haplotypes (FH). Deterioration condition/death were treated as competing 
risks for finding a donor; therefore for all patients with 2 FH a donor was found, hence the flat 
line. See Table 2.
HLA haplotypes, UD search and HSCT
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Table 3. Patient/donor/HSCT characteristics (Transplantation analysis)
No FH
n=159
1 FH
n=146
2 FH
n=43
Total
n=348 p value
Patient age at HSCT, median (range)* 31 (<1 – 66) 30 (<1 – 67) 34 (<1 – 66) 31 (<1 – 67) .744
Donor age at HSCT, median (range)* 36 (20 – 58) 33 (19 – 62) 31 (21 – 49) 34 (19 – 62) .006
Year of HSCT, median (range)* 2004  
(1991 – 2008)
2005
(1989 – 2008)
2002
(1987 – 2008)
2004
(1987 – 2008)
.080
Days to HSCT, median (range)* 472  
(79 – 5352)
403 
(91 – 9313)
360 
(71 – 6774)
411 
(71 – 9313)
.418
HSCT Center, n (%)# .525
   Leiden 66 (42) 67 (46) 21 (49) 154 (44)
   Rotterdam 42 (26) 42 (29) 8 (19) 92 (26)
   Utrecht 51 (32) 37 (25) 14 (33) 102 (29)
Female (D) to male (P), n (%)# 32 (20) 20 (14) 5 (12) 57 (16) .212
ABO mismatch, n (%)# 77 (48) 76 (52) 21 (49) 174 (50) .969
CMV negative (D) to positive (P), n (%)# 39 (25) 35 (24) 9 (23) 83 (24) .971
Diagnosis, n (%)+ .305
   Acute leukemia 67 (42) 62 (43) 16 (37) 145 (42)
   Chronic leukemia 28 (18) 20 (14) 4 (9) 52 (15)
   Plasma cell disorder 11 (7) 6 (4) 4 (9) 21 (6)
   MDS/MPS 13 (8) 18 (12) 9 (21) 40 (12)
   Bone marrow failure 11 (7) 12 (8) 6 (14) 29 (8)
   Inherited disorder 13 (8) 11 (8) 3 (7) 27 (8)
Disease type# .178
   Myeloid malignancy 73 (46) 75 (52) 26 (61) 174 (50)
   Lymphoid malignancy 61 (39) 47 (32) 8 (19) 116 (34)
   Non- malignant 24 (15) 23 (16) 9 (21) 56 (16)
ATG, n (%)# 114 (72) 97 (66) 23 (54) 234 (67) .150
Myeloablative conditioning, n (%)# 100 (64) 99 (68) 29 (67) 228 (66) .733
Ciclosporin, n (%)# 138 (87) 120 (82) 32 (74) 290 (83) .331
TCD, n (%)# 63 (40) 57 (39) 21 (49) 141 (41) .505
Campath, n (%)# 50 (33) 42 (29) 17 (41) 109 (32) .346
TBI, n (%)# 108 (68) 100 (69) 28 (65) 236 (68) .916
CR/CP/non-malignant at HSCT, n (%)# 89 (56) 86 (59) 21 (49) 196 (56) .150
Bone marrow graft, n (%)# 77 (48) 75 (51) 29 (67) 181 (52) .084
DPB1 match, n (%)# 23 (15) 22 (15) 9 (21) 54 (16) .299
FH: frequent haplotype; *Kruskal-Wallis test; # Pearson’s Chi Square test; +Fishers’ exact test. All days 
are calendar days.
haplotype frequencies requesting more donor blood samples for confirmatory typing 
at the start of the search seems reasonable in order to decrease the delay in finding 
an UD.108 In our cohort the number of patients with 1 or 2 FH was substantial (38%); 
therefore the effect of using HLA haplotypes in UD searches can be very relevant.
Our transplantation results are in concordance with results from Petersdorf et al.30 and 
the Japanese study48, showing less ≥ grade II aGVHD in the patients with FH. Although 
36
3there are genetic differences between our population and the Japanese population, the 
principle appears to be similar. Because the patients and donors had identical HLA-A, -B, 
-C, -DRB1, and -DQB1 alleles, ≥ grade II aGVHD could not have been caused by differences 
in these HLA genes, which supports the idea that within the MHC additional genes that 
encode transplantation antigens are present and/or regulate the immune response to 
minor transplantation antigens. Patients with FH in highest LD between both HLA-A and 
-C or -B and HLA-C or -B and -DRB1 had the lowest incidence of ≥ grade II aGVHD 
suggesting that these additional genes might be located both telomeric and centromeric 
to HLA-B. Although our analysis demonstrated no difference in overall survival, the 
decreased risk of ≥ grade II aGVHD is important to note. Research showing that quality 
of life is negatively impacted by aGVHD118 and health care costs are significantly higher 
with the development of aGVHD119 indicate the importance of reducing aGVHD. 
Onset of aGVHD might not depend only on non-HLA gene matching between 
donor and patient, but also on immune regulation possibly affected by the presence 
Figure 2. Cumulative incidence of A 
mortality, B ≥ grade II aGVHD and C 
relapse of patients with no, 1 or 2 frequent 
haplotypes (FH). See for statistics Table 4.
HLA haplotypes, UD search and HSCT
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of a certain SNP in cytokine encoding genes within the MHC region in either patient 
or donor. Next to the previous mentioned genetic variants of TNF, MICA/MICB and 
Msat markers many other genes have the potential to influence immune functions or 
lead to different susceptibility to aGVHD such as TAP1/TAP2 and LMP2/LMP7 genes, 
complement and the heat shock proteins. Immunogenetic profiles for successfully 
transplanted individuals including parameters as HLA haplotypes and cytokine gene 
polymorphism may contribute to a better understanding of the underlying mechanisms 
leading to aGVHD.94
Table 4. Frequent haplotypes associated with HSCT outcome
n
Crude associations
(univariate analysis)
Corrected associations 
(multivariate analysis)
Mortality 347 HR (95% CI) p value HR (95% CI)* p value
No FH 158 1.00 (ref) 1.00 (ref)
1 FH 146 0.95 (0.68 – 1.33) .770 0.96 (0.67 – 1.39) .840
2 FH 43 0.82 (0.47 – 1.42) .480 0.70 (0.36 – 1.36) .290
1 or 2 FH 189 0.93 (0.68 – 1.28) .660 0.91 (0.63 – 1.30) .590
No FH 158 1.00 (ref) 1.00 (ref)
A-C or -B FH 19 1.06 (0.57 – 1.99) .850 0.84 (0.37 – 1.90) .680
C or B-DR FH 81 1.04 (0.71 – 1.53) .840 1.04 (0.67 – 1.61) .850
A-C or B-DR FH 107 0.81 (0.57 – 1.16) .250 0.82 (0.55 – 1.22) .330
≥ grade II aGVHD 322 HR (95% CI) p value HR (95% CI)# p value
No FH 148 1.00 (ref) 1.00 (ref)
1 FH 134 0.68 (0.40 – 1.18) .170 0.59 (0.34 – 1.03) .064
2 FH 40 0.32 (0.10 – 1.06) .063 0.31 (0.09 – 1.04) .057
1 or 2 FH 174 0.60 (0.36 – 1.01) .056 0.53 (0.31 – 0.91) .021
No FH 148 1.00 (ref) 1.00 (ref)
A-C or -B FH 17 0.86 (0.27 – 2.73) .790 0.89 (0.25 – 3.18) .850
C or B-DR FH 72 0.60 (0.29 – 1.23) .160 0.58 (0.27 – 1.22) .150
A-C or B-DR FH 101 0.57 (0.31 – 1.06) .075 0.49 (0.26 – 0.92) .026
Relapse 291 HR (95% CI) p value HR (95% CI)+ p value
No FH 134 1.00 (ref) 1.00 (ref)
1 FH 123 0.86 (0.55 – 1.34) .500 0.97 (0.60 – 1.55) .880
2 FH 34 0.64 (0.29 – 1.44) .280 0.70 (0.31 – 1.62) .410
1 or 2 FH 157 0.85 (0.55 – 1.29) .440 0.95 (0.60 – 1.48) .810
No FH 134 1.00 (ref) 1.00 (ref)
A-C or -B FH 14 0.92 (0.33 – 2.58) .880 1.02 (0.34 – 3.01) .980
C or B-DR FH 66 0.80 (0.46 – 1.40) .430 0.79 (0.42 – 1.45) .440
A-C or B-DR FH 91 0.87 (0.55 – 1.39) .570 0.97 (0.61 – 1.55) .890
*Mortality model corrected for: donor age, HSCT year, ABO match, CMV match, disease type, TCD of 
the graft, Campath, disease status at HSCT and conditioning. #aGVHD model corrected for: patient age, 
Campath and conditioning. +Relapse model corrected for: gender match, CMV match, disease type, 
ATG, Ciclosporin, Campath, donor age and conditioning.
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3Morishima et al.48 demonstrated that the HLA haplotype itself affects incidence of 
aGVHD. These findings suggest that the genetic factor of specific haplotypes would 
contribute to reducing or increasing the risk of aGVHD. In HSCT, aGVHD has been 
known to result mainly from donor T cells recognizing minor histocompatibility antigens 
(mHags) presented on HLA molecules of a recipient’s organs.120 HLA alleles in each 
haplotype might present different immunodominant peptides to T cells and give rise 
to different alloreactivity in HLA matched UD HSCT. Furthermore, HLA-DR15 positive 
patients transplanted from HLA-matched donors have shown a reduced incidence of 
aGVHD for HLA-DR15 positive patients transplanted from HLA-matched donors.121
The most frequent 5 locus allele level typed HLA haplotypes found in the Dutch 
population were comparable to other Northwest European populations. The sample 
population was in Hardy Weinberg, therefore we conclude the sample was free from 
selection bias and was large enough to estimate reliable haplotypes from. Another major 
strength of our analysis is that we used competing risk analysis in both UD search and 
transplantation analysis preventing overestimated estimates. Because we used FH as a 
Figure 3. Cumulative incidence of A 
mortality, B ≥ grade II aGVHD and C 
relapse of patients without frequent 
haplotypes (FH) or FH in high linkage 
disequilibrium (LD) between HLA-A to 
HLA-C or -B (FH ACB), HLA-C or -B to 
HLA-DRB1 (FH CBDR) or both (ACBDR). 
See for statistics Table 4.
HLA haplotypes, UD search and HSCT
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proxy for HLA haplotype matching there is certain margin of error in the transplantation 
analysis, we suspect that the actual association might be even stronger. Many variables 
could have confounded our results; we choose to check every variable for every end 
point separately and see whether they influenced HSCT outcome in our study population. 
For patients with one or two FH more often younger donors were found and donor age 
was statistically significant different in the three FH groups. Donor age was previously 
identified to influence HSCT outcome;122 we included it in the mortality and relapse 
model to correct for confounding (after testing). Time to transplant9 also could have 
been a potential confounder, because patients with 1 or 2 FH had shorter UD search 
times. However, time from diagnosis to HSCT was not different in the three FH groups 
and was not identified as a confounding variable in our data. The use of BM versus PBSC 
was borderline statistically significant different in the three FH groups, patient with 1 
or 2 FH more often received a BM graft. Additionally, these patients were more often 
pediatric patients. This could have potentially influenced the lower aGVHD rates we saw 
in patients with 1 or 2 FH123. Use of BM was not identified as a confounding factor in 
our population, but we did correct for patient age in the aGVHD model. DPB1 matches 
were not identified as a confounding factor in any of the analyses and did therefore 
not influence our results.25 We believe we have dealt with possible confounding from 
these variables in the appropriate way. The use of the classical Delta for quantifying LD 
may constitute a potential weakness in our analysis, because the Delta calculations are 
probably only an estimation of the true LD. Furthermore, because the Delta is linked to 
the GF it is difficult to compare the Delta between haplotypes with different frequencies. 
More elaborate calculations are available, however they are not always possible to 
calculate or easier to interpret, especially when applied to 5 locus haplotypes. Also, the 
categorization into three groups (HLA-A and -C or -B loci, HLA-C or -B and -DRB1 loci or 
both parts) was based on the LD. Patients with and without FH were similar in receiving 
TCD, however the methods used for TCD were very heterogeneous. Because of this 
heterogeneity we were unable to clearly elucidate the effect of TCD on the association 
between FH and ≥ II aGVHD, which could have influenced our results. Regardless of 
these flaws; we believe the results still have meaningful value. 
Our results confirm and extend evidence that there are non-HLA gene coding 
regions within the MHC which have a significant impact on transplantation related 
complications, in particular the incidence of ≥ grade II aGVHD. We conclude that there 
is more to successful HSCT than matching for classical HLA class I and II genes.
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ABSTRACT
Previously we showed that with increasing number of amino acid (AA) differences in 
single HLA class I mismatched molecules the probability of T cell (CTL) alloreactivity 
decreases. It is unlikely that every AA difference will affect CTL alloreactivity in a similar 
way; we hypothesized that the effect of an AA difference may be dependent on its 
position and/or physicochemical properties. We selected 131 donor-recipient pairs with 
either a single HLA-A or -C mismatch in the graft-versus-host (GvH) direction and that 
were compatible for HLA-B, -DRB1 and -DQB1. The alloreactive cytotoxic T lymphocyte 
precursor (CTLp) frequency was determined and was associated with the AA differences 
between the single HLA class I mismatches. In the β sheet only AAs that are non-
compatible in their physicochemical properties affect CTL alloreactivity, while in the α 
helices both compatible and non-compatible AAs affect the CTLp assay. Positions 62, 
63, 73, 76, 77, 80, 99, 116, 138, 144, 147 and 163 were bivariately associated with the 
CTLp assay, irrespective of the total number of AA differences. In multivariate analysis 
positions 62, 63, 73, 80, 116, 138, 144 and 163 were found to be most predictive for a 
negative CTLp assay. These results formed the basis for a weighted predictive mismatch 
score; pairs with the highest mismatch scores are estimated to be 13 times more likely 
to have a negative CTLp. This new algorithm may be a tool in donor selection for 
hematopoietic stem cell transplantation.
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4INTRODUCTION
One of the major issues in hematopoietic stem cell transplantation (HSCT) is selection 
of a suitable donor when a fully human leukocyte antigen (HLA) matched donor is not 
available. A significant number of patients have to be transplanted with hematopoietic 
stem cells from a mismatched donor. The immunogenicity of MHC molecules may 
differ; therefore the challenge is to select a donor for whom the HLA mismatch of the 
recipient is not very immunogenic. This is feasible as confrontation with foreign MHC 
will not always lead to an alloreactive immune response.124 Previously we have shown 
that a low cytotoxic T lymphocyte precursor (CTLp) frequency of the donor against the 
HLA mismatch of the recipient is associated with good clinical results of HLA class I 
mismatched HSCT.37 Some MHC class I mismatches are indeed associated with low or 
undetectable CTLp frequencies, whereas high CTLp frequencies can be seen in other 
HLA class I matched donor-recipient pairs.124-126 
Previously we investigated whether CTL alloreactivity could be predicted by the number 
of AA differences on the α helices and the β sheet of single MHC class I mismatched 
molecules in 74 donor-recipient pairs.127 Quantification of the allogeneic CTL response 
in vitro was obtained by the CTLp assay,36 because it has been proven to be clinically 
relevant in predicting allogeneic HSCT outcome.128-134 These studies focused on the AA 
differences on those parts of MHC class I molecules that are important for T cell receptor 
(TCR) contact and/or peptide binding. Motifs relevant for MHC-TCR interaction are 
predominantly located in the α helices and peptides binding residues are predominantly 
located in the β sheet.33,34,135-138 The preliminary results showed that CTL alloreactivity could 
be predicted to certain extend. Single HLA-C mismatches with five or more AA differences 
on the α helices and five or more AA differences on the β sheet did not lead to T cell 
mediated alloreactivity in vitro. So, with increasing number of AA differences the probability 
of a negative CTLp assay increased significantly. In that pilot study the group of single 
HLA-A, and -B mismatches was too small and included too many mismatches with few AA 
differences to enable generalization of these findings to all MHC class I molecules. 
The humoral alloimmune response to HLA class I mismatches can be successfully 
predicted by the HLAMatchmaker algorithm.39,139 As HLAMatchmaker takes only 
antibody accessible sites of the HLA molecules into consideration, it is not a suitable 
tool to predict CTL alloreactivity.140 Previous attempts to associate predictive levels of 
cellular alloimmunity with HSCT outcome have been unsuccessful.42,141,142 So far, the 
actual outcome of the CTLp assay is used for donor selection in our center. The real 
challenge is to predict cellular alloimmune responses, especially because the CTLp 
assay is a complicated and time consuming test. In the present study we investigated 
a larger population of single HLA class I mismatched pairs and attempt to extend our 
previous findings to other HLA class I molecules.
It is logical to assume that not every AA difference between MHC class I molecules 
may affect CTL alloreactivity in a similar way. Both position (specific positions, α helices 
or β sheet)143 and physicochemical properties (size, polarity and charge) of the AAs 
CTL alloreactivity predicted by AA polymorphism
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involved may play a role.144-146 We aim to develop an algorithm in which we incorporate 
all aspects of the AA differences to predict CTL alloreactivity against single MHC class 
I mismatches and to use this as a tool for single HLA class I mismatched unrelated or 
related donor selection in HSCT.
PATIENTS AND METHODS
Donor-recipient pairs
In total 164 donor-recipient pairs registered by the Europdonor Foundation from 1990 
to 2008, for whom successful CTLp assays were performed, were available for this study. 
The patients were treated at Dutch hematopoietic stem cell transplantation centers. The 
150 unrelated donors originated from national or international donor registries and 14 
donors were related. All donor-recipient pairs had a single HLA-A, -B or -C mismatch in 
the GvH direction and were compatible for HLA-DRB1 and -DQB1. Donor-recipient pairs 
with single HLA class I mismatches without AA differences at the previously specified 
positions in the α helices or the β sheet [HLA-C*03:03-03:04 (n=11), HLA-C*07:01-07:18 
(n=1) and HLA-B*35:02-35:04 (n=1)] were excluded from analysis. The reason for this is 
that the AA differences in these combinations do not affect T cell recognition, as they 
are located on parts of the molecule that are not involved in the interaction with the TCR. 
This study included only HLA-A (n=55) and -C (n=76) mismatched pairs, because 
single HLA-B (n=20) mismatched pairs were rare and distinctive in their number and 
position of AA differences. Finally, 131 single MHC class I mismatched donor-recipient 
pairs were included in the analysis; the specific HLA mismatches are shown in Table 1.
HLA genotyping and AA sequencing
All donors and patients were typed at high resolution for HLA-A, -B, -C, -DRB1, -DQB1 
as described previously.125 Briefly, polymerase chain reaction sequence specific primer 
(PCR-SSP) for high resolution allele typing and sequence based typing (SBT), for part of the 
HLA-C alleles, were used. AA sequences were obtained by using the European Bioinformatics 
Institute website.22 MHC class I mismatches were examined for AA differences in the α1/2 
domain, with specific interest in positions 50-85 and 138-179 in the α helices and positions 
4-12, 21-28, 32-37, 94-102, 112-118 and 123-126 in the β sheet.127 
CTLp assay
The CTLp assays were performed as described by Zhang et al,36 with minor modifications 
as described by Oudshoorn et al.125 CTLp assays were performed in the graft-versus-
host (GvH) direction. A negative CTLp assay was defined as ≤ 1 recipient specific CTL 
per 106 peripheral blood lymphocytes.
Physicochemical properties of AAs
We divided the AAs into five groups according to their physicochemical properties 
(as listed in Table 2). All AA differences of the single MHC class I mismatched pairs 
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4were categorized into compatible (within group) or non-compatible (between group) 
AA differences. We hypothesized that compatible AA differences may have a different 
influence on CTL alloreactivity than non-compatible AA differences. 
Statistical analysis
We investigated the association of the number of all, non-compatible and compatible 
AA differences on the α helices and β sheet (combined and separately) with the 
occurrence of a negative CTLp assay. The AA difference variables were categorized into 
Table 1. HLA class I mismatches (GvH direction) in the study population
HLA-A (n=55)
01:01-03:01 02:01-34:02 24:02-31:01
01:01-24:02 02:01-68:01 (n=3)* 24:03-24:02
01:01-68:01 (n=2)* 02:03-02:07 25:01-26:01
02:01-01:01 02:05-02:01 (n=2)* 25:01-34:02
02:01-02:05 (n=3)* 02:05-24:02 26:01-25:01
02:01-02:06 (n=5)* 03:01-11:01 31:01-02:01
02:01-02:11 11:01-03:01 31:01-30:01 (n=2)*
02:01-03:01 11:01-26:01 32:01-01:01
02:01-11:01 11:01-68:01 32:01-32:02
02:01-23:01 11:04-11:01 32:01-68:01
02:01-26:01 (n=2)* 11:04-68:02 68:01-32:01
02:01-31:01 24:02-02:01 68:01-69:01
02:01-32:01 (n=2)* 24:02-23:01 68:02-68:01
02:01-33:01 24:02-24:03 (n=2)*
HLA-C (n=76)
01:02-02:02 (n=3)* 03:04-06:02 07:02-05:01
01:02-03:03 (n=2)* 03:04-07:01 07:02-15:02
01:02-03:04 (n=2)* 04:01-02:02 07:04-05:01 (n=2)*
01:02-07:02 04:01-16:01 (n=3)* 08:02-08:01
01:02-14:02 05:01-01:02 12:03-07:01 (n=2)*
02:02-01:02 (n=2)* 05:01-03:04 14:02-15:02 (n=4)*
02:02-03:03 (n=2)* 05:01-14:02 15:02-02:02
02:02-03:04 05:01-15:02 15:02-03:04 (n=2)*
02:02-05:01 (n=2)* 05:01-16:04 15:02-04:01 (n=2)*
02:02-07:01 07:01-02:02 15:02-14:02
02:02-07:02 07:01-03:03 15:02-16:02
02:02-14:02 07:01-05:01 (n=2)* 16:01-04:01
02:02-15:02 (n=4)* 07:01-07:02 16:01-05:01
03:03-04:01 (n=4)* 07:01-12:03 (n=2)* 16:01-07:01
03:03-07:02 07:01-15:02 16:02-07:01
03:04-01:02 07:02-01:02 16:04-05:01
03:04-04:01 07:02-02:02 (n=2)* 17:01-06:02
*Of the 65 multiple donor-recipient pairs, 14 (21.5%) had aberrant CTLp assays.
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three groups (tertiles) based on the distribution over the HLA mismatches. We chose 
to use tertiles to ensure objectivity and even sized categories. In all variables the group 
with the lowest number of AA differences was set as reference. Differences in discrete 
variables (all AA difference variables (in tertiles), HLA-DPB1 mismatching (yes/no) and 
killer-cell immunoglobulin-like receptor (KIR) ligand mismatching (yes/no) between 
positive and negative CTLp assay were examined with Pearson’s Chi Square test.
Odds ratios (OR), 95% confidence intervals (95% CI) and p-values were obtained using 
logistic regression analysis to quantify the association between the number of AA differences 
and negative CTLp assay. In addition we analyzed each specific different AA position (yes/
no) separately to test for association with negative CTLp assay. All AA positions with a 
significance level below p-value ≤ .200 were tested in bivariate analysis correcting for the 
total number of AA differences. Those that remained associated with negative CTLp assay 
at a significant level of p-value ≤ .200 were selected for multivariate analysis. 
Multivariate analysis using a backward stepwise approach (based on the likelihood 
ratio test) was conducted to identify the most predictive model for negative CTLp 
assay. Under this approach, we start with fitting a model with all the AA positions of 
interest (identified in univariate and bivariate analysis). Then the least significant AA 
position is dropped. We continue by successively re-fitting reduced models and then 
re-considering all dropped AA positions for re-introduction into the model. This means 
that two separate significance levels must be chosen for deletion from the model and for 
adding to the model (the entry p-value is set at .050 and the removal p-value at .100). 
The β estimates (regression coefficients) of the AA positions remaining in the final 
prediction model were used to define a weighted predictive AA ‘mismatch score’. 
This mismatch score was also categorized into three groups (tertiles) based on the 
distribution over the donor-recipient pairs and the group with the lowest scores was 
set as reference. For both the multivariate prediction and the final model we included 
model evaluation statistics and Somer’s D and c-statistics as a measure of association.
See for statistical decision making Figure 1. Two sided p-values ≤ .050 were considered 
statistically significant and all analyses were performed using SPSS 17.0 for Windows.
Table 2. Five groups of AAs according to their physicochemical properties
Negatively charged Asp (D), Glu (E)
Positively charged Lys (K), His (H), Arg (R)
Polar / Neutral Gly (G), Thr (T), Ser (S), Gln (Q), Asn (N)
Apolar Leu (L), Ile (I), Val (V), Met (M), Cys (C), Ala (A), Pro (P)
Large / Apolar Trp (W), Phe (F), Tyr (Y)
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4Figure 1. Statistical decision making
RESULTS
We tested whether CTL alloreactivity is dependent on position and/or physicochemical 
properties of AA differences in mismatched HLA class I molecules. The study population 
consisted of 55 donor-recipient combination mismatched for HLA-A and 76 for HLA-C, 
of which 79 had a positive and 52 had a negative CTLp assay. The polymorphic AA 
positions are very different among these mismatched molecules. HLA-A molecules are 
more polymorphic in the α helices and the HLA-C molecules are more polymorphic in 
the β sheet. Also the total number of AA differences varies between the mismatches 
[median (range): 11 (1-22)]. 
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Of the 131 donor-recipient pairs, 97 had either one (n=66) or two (n=31) 
mismatched HLA-DPB1 allele(s) in the GvH direction. For 3 donor-recipient pairs the 
HLA-DPB1 match grade was unclear due to missing typing of the donor. Of the 76 
HLA-C mismatched donor-recipient pairs, 19 had a killer-cell immunoglobulin-like 
receptor (KIR) ligand mismatch in the GvH direction and 57 were matched for their KIR 
ligands. Neither HLA-DPB1 nor KIR ligand mismatching was associated with the CTLp 
assay (data not shown).
With increasing number of AA differences in both the α helices and β sheet the 
probability of a negative CTLp assay increased statistically significant. In the α helices all 
AA differences contribute to this effect, while in the β sheet only AA differences with non-
compatible physicochemical properties do (Figure 2). Therefore, only AA differences 
in the β sheet are categorized in compatible and non-compatible according to their 
physicochemical properties. Next, we combined the number of all AA differences in the 
α helices and only the number of non-compatible AA differences in the β sheet; the 
Figure 2. Observed association between the number of noncompatible (NC) (A: Chi square = 
6.151; p = 0.046) and compatible (C) (B: Chi square = 7.493; p = 0.024) AA differences on the α 
helices and the probability of a negative CTLp assay. Observed association between the number of 
noncompatible (NC) (C: Chi square = 8.530; p = 0.046) and compatible (C) (D: Chi square = 2.156; 
p = 0.340) AA differences on the β sheet and the probability of a negative CTLp assay.
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4odds that the CTLp assay is negative is almost five times larger for mismatches with ≥9 
AA differences compared to mismatches with 0-5 AA differences (Table 3 and Figure 3). 
Twelve AA positions (62, 63, 73, 76, 77, 80, 99, 116, 138, 144 and 147) in both α 
helices and β sheet were identified to be associated with a negative CTLp assay, even 
after correction for the total number of AA differences (data not shown). Eight AA 
positions (62, 63, 73, 80, 138, 144, 163 and 116) remained in the final model (after 
backward stepwise selection) and are therefore most predictive for a negative CTLp 
assay (Table 4).
Table 3. Association between the number of all AA difference on the α helices combined with the 
number of non-compatible AA differences on the β sheet and the probability of a negative CTLp 
assay (univariate analysis)
n OR (95% CI)* p-value
α helices (all) + β sheet (non-compatible) .016
0-5 27 1.00 (ref)
6-8 44 2.51 (0.80-7.93) .116
9-19 60 4.70 (1.57-14.06) .006
*Odds ratios and 95% confidence intervals. 
Table 4. Association between specific positions of AA differences and the probability of a negative 
CTLp assay (multivariate analysis)
β estimate OR (95% CI)* p-value
62 2.232 9.32 (1.52-57.11) .016
63 -2.111 0.12 (0.01-1.02) .052
73 1.159 3.19 (1.26-8.08) .015
80 1.042 2.84 (1.19-6.78) .019
138 1.149 3.15 (0.84-11.85) .089
144 -1.622 0.20 (0.03-1.35) .097
163 1.081 2.95 (1.20-7.26) .019
116 .035
116 non-compatible 0.449 1.57 (0.65-3.80) .321
116 compatible -1.976 0.14 (0.02-1.03) .054
Overall model evaluation Chi Square p-value
Likelihood ratio test 35.739 .000
Measure of concordance Test statistic
Somer’s D .582
C-statistics .791
*Odds ratios and 95% confidence intervals. The β estimate (regression coefficient) represents the magnitude 
of the association with negative CTLp assay. Overall model evaluation statistics examine the predictive 
improvement of the fitted model compared to the intercept only model. Somer’s D and c-statistics represents 
measures of association; whether predicted probabilities agree with actual outcomes.
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Figure 3. Observed association between 
the number of all AA (AA) differences on 
the α helices combined with the number 
of noncompatible AA differences on the β 
sheet and the probability of a negative CTLp 
assay (Chi square = 8.854; p = 0.012).
Figure 4. Predicted association between the 
weighted predictive mismatch score and the 
probability of a negative CTLp assay (Chi 
square = 28.770; p = 0.000)
Their β estimates (regression coefficients) formed the basis of the ‘weighted 
predictive AA mismatch score’ for a negative CTLp assay. Mismatched pairs with the 
highest mismatch scores are 13 times more likely to have a negative outcome of the 
CTLp assay (Table 5 and Figure 4). Correction for the total number of AA differences by 
including this variable in the model did not alter the association.
DISCUSSION
Attempts to predict molecular interactions that lead to CTL alloreactivity have not yet 
resulted in clear-cut results. We retrospectively analyzed the association between CTL 
alloreactivity in vitro and single HLA-A and -C mismatches in 131 donor-recipient pairs. 
Our results show that compared to HLA alleles that are more similar to self HLA alleles, 
divergent HLA alleles more often do not lead to T cell mediated alloreactivity in vitro. 
This is in line with the previously proposed hypothesis that the possibility for TCR-MHC 
binding decreases if allogeneic MHC differs too much from autologous MHC.127 Next 
we looked at AAs that are (non-)compatible in their physicochemical properties. In 
the β sheet only AAs that are distinctive in their physicochemical properties affect 
CTL alloreactivity negatively. This suggests that in contrast to compatible AAs, non-
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4compatible AA differences influence the peptide binding repertoire in such a way that a 
MHC-peptide complex that is very distinct from self MHC-peptide complexes prevents 
allorecognition. In the α helices both compatible and non-compatible AAs affect the 
CTLp assay, implying that in MHC-TCR interaction all AA differences in the α helices 
have similar effects on allorecognition. 
Furthermore, we were able to identify a differential importance of AA differences at 
specific positions for the T cell mediated alloresponse to HLA class I mismatches. 
AAs at position 62, 76 and 163 point up from the antigen binding site and are 
believed to be in direct contact with the TCR.33,136 AAs at position 63, 73, 77, 80, 147, 99 
and 116 point toward the antigen binding site and are believed to be involved in peptide 
binding33. Position 63 and 99 form part of pocket A and B, 73 of pocket C, 147 of pocket 
E and 77, 80 and 116 of pocket F34,147,148 and residue 116 plays a key role in determining 
the specificity of the F pocket.148 Some of these positions and specific allele mismatches 
have been associated with transplant outcome; although not a single position or allele 
mismatch was consistently identified to be detrimental or favourable.42-47,149 Differences 
in study -design and/or -population may be responsible for the inconsistent results. 
The association between AA polymorphism and the CTLp assay that we found is 
not absolute and may be diluted because of the additional impact of non inherited 
maternal antigens,150 minor histocompatibility antigens or indirect recognition of 
a peptide derived from the mismatched HLA molecule in one of the shared HLA 
molecules. Furthermore, the TCR repertoire of an individual is based on self MHC and is 
therefore unique while alloreactivity is often based on cross reactivity by virus-specific 
memory T cells.151 Together this may explain the unpredictability of T cell responses. 
Table 5. Association between the predictive mismatch score and the probability of a negative 
CTLp assay (univariate analysis)
n Score OR (95% CI)* p-value
Score .000
Low 40 < 1.081 1.00 (ref)
Medium 47 1.081-2.218 2.66 (0.92-7.69) .072
High 44 > 2.218 13.51 (4.58-39.91) .000
Overall model evaluation Chi Square p-value
Likelihood ratio test 29.905 .000
Measure of concordance Test statistic
Somer’s D .509
C-statistics .755
*Odds ratios and 95% confidence intervals. The β estimate (regression coefficient) represents the magnitude 
of the association with a negative CTLp assay. Overall model evaluation statistics examine the predictive 
improvement of the fitted model compared to the intercept only model. Somer’s D and c-statistics represents 
measures of association; whether predicted probabilities agree with actual outcomes.
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The basis of T cell mediated alloreactivity has been debated extensively and has 
generally resulted in two possible models, a MHC- and a peptide- driven mechanism. 
The first proposes that the alloreactive TCR directly recognizes polymorphisms in the 
allo MHC molecules independently of the bound peptide and thereby adopting novel 
docking modes.152 The second suggests that responses to bound peptides that differ 
in sequence as well as peptides adopting different conformations when bound to the 
allo or self MHC molecules are most important in triggering alloreactivity.135,153-155 If 
molecular mimicry is the basis of the alloimmune response this would explain why 
increasingly divergent allo MHC molecules are less likely to be targets for T cell 
mediated cross-reactivity.35 Probably both mechanisms play a role,35,156,157 which would 
explain why the strongest effect is found when combining both the number of AA 
differences in α helices (TCR contact) and the β sheet (peptide binding region). 
In this study we were able to reproduce previous findings127 and extend them to single 
mismatched HLA-A molecules. Unfortunately the number of single HLA-B mismatches 
was too low to show that a similar algorithm applies for HLA-B as well. Due to the 
relative low numbers we were also not able to stratify for HLA-A and -C. Therefore we 
could not test whether the mode of interaction with TCRs is similar for these two types 
of molecules. Although promising, these results need to be prospectively validated in a 
larger and extended population before the algorithm can be used for single HLA class I 
mismatched unrelated or related donor selection in HSCT. What these results do clearly 
show is that an HLA Class I mismatch with few or small AA differences is not necessarily 
better than an HLA Class I mismatch with numerous or large AA differences. The next 
step is to evaluate the clinical value of the weighted prediction mismatch score for 
transplant outcome.
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ABSTRACT
Previously we developed a weighted amino acid (AA) mismatch score predictive for 
cytotoxic T cell (CTL) alloreactivity (in vitro CTLp assay) based on the structure of the HLA 
class I molecule. Aim of this study is to confirm the clinical relevance of the CTLp assay 
and to validate the AA mismatch score as an alternative and easy to use tool to predict 
permissible mismatches in hematopoietic stem cell transplantation (HSCT). We selected 
patients transplanted with a 9/10 single HLA class I mismatched graft (n=171) at three 
Dutch HSCT centers. A CTLp assay was performed in 73 donor-recipient pairs. As a 
control we selected 168 10/10 HLA matched pairs that were matched to the 9/10 single 
HLA class I mismatched pairs for HSCT year, donor type, patient age and diagnosis. We 
observed that pairs with a negative CTLp assay had statistically significant decreased 
incidence of mortality after HSCT comparable to that of 10/10 HLA matched pairs. 
However, the weighted AA mismatch score did not significantly predict any HSCT end 
point of interest. Further investigation is needed to unravel the mechanisms involved in 
causing the beneficial effect of a negative CTLp assay, before other alternative tools to 
predict HSCT outcome may be developed.
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5INTRODUCTION
Recently we proposed an algorithm predictive for cytotoxic T cell (CTL) alloreactivity 
(in vitro CTLp assay) based on the structure of human leukocyte antigen (HLA) class I 
molecules using number, position and physicochemical compatibility of mismatched 
amino acid (AA) residues involved in T cell receptor (TCR) contact and/or peptide 
binding.158 For development of this algorithm we assumed that not every AA in the 
structure of an HLA molecule will have similar effects on CTL alloreactivity, resulting 
in a weighted AA mismatch score. The reason for developing this algorithm was the 
fact that the CTLp assay itself has been proven to be clinically relevant in predicting 
hematopoietic stem cell transplantation (HSCT) outcome.37,128-134 Our recent158 and 
previous research127 shows that for single 9/10 HLA class I mismatched molecules 
with increasing AA differences the probability of a CTL alloreaction in vitro decreases. 
Mismatches leading to a negative CTLp assay are acceptable for HSCT, however so far 
we were not able to show an effect independently from the CTLp assay.37 The CTLp 
assay is a difficult and laborious assay and is not used in all HSCT centers. Alternative 
approaches are warranted and therefore, validation of the AA mismatch score is needed 
to allow translation from CTL alloreactivity to HSCT outcome. Ideally the AA mismatch 
score could be used for donor selection replacing the CTLp assay to distinguish 
permissive from non-permissive single HLA class I mismatches. 
In this report we test the hypothesis that a high AA mismatch score is associated 
with a lower incidence of mortality and/or acute graft-versus-host disease (aGVHD), in 
line with the previously observed beneficial effect of a negative CTLp assay. Additionally 
we verify the beneficial effect of a negative CTLp assay itself on HSCT outcome.
PATIENTS AND METHODS
Donor-recipient pairs
Pediatric (n=112) and adult patients (n=227) with malignant (n=296) and non-
malignant (n=41) diseases were included in this study. Patients were treated at three 
Dutch HSCT centers: Leiden university medical center (LUMC), Erasmus medical center 
(MC) and university medical center Utrecht (UMCU). Donors originated from national or 
international donor registries, 20 were family donors. Clinical patient information was 
made available by the HOVON Data Center through the European group for Blood and 
Marrow Transplantation (EBMT) patient database. 
To study the CTLp assay in association with HSCT outcome we selected patients 
transplanted with a 9/10 single HLA mismatched graft. All donor-recipient pairs (n=171) 
had a single HLA-A, -B or -C mismatch in the graft-versus-host (GvH) direction and 
were compatible for HLA-DRB1 and -DQB1. In 73 of the 171 donor-recipient pairs a 
CTLp assay had been performed. CTLp assays were performed on a clinical indication 
and are not evenly distributed among the HSCT centers. As controls we selected 
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168 10/10 HLA-A, -B, -C, -DRB1, -DQB1 matched donor-recipient pairs from all three 
HSCT centers, matched to the 9/10 single HLA class I mismatched donor-recipient pairs 
for HSCT year, donor type, patient age and diagnosis (total cohort: n=339).
To study the clinical relevance of the AA mismatch score we determined the 
association between HSCT outcome and the AA mismatch score in the same cohort 
of 9/10 HLA mismatched donor-recipient pairs (n=171) regardless the outcome of the 
CTLp assay. To get two distinct groups we used only the low and high score categories 
and excluded the medium score (n=39).
HLA genotyping and weighted AA mismatched score
All donors and patients were typed at the allele level for HLA-A, -B, -C, -DRB1, -DQB1 
as described previously.125 Briefly, polymerase chain reaction sequence specific primer 
(PCR-SSP) for high resolution allele typing and sequence based typing (SBT), for part of the 
HLA-C alleles, were used. Development of the weighted AA mismatch score was described 
previously.158 Briefly, AA sequences were obtained using the European Bioinformatics 
Institute website.22 HLA class I mismatches were examined for AA differences in the α1/α2 
domain, specifically positions 50-85 and 138-179 in the α helices and positions 4-12, 21-28, 
32-37, 94-102, 112-118 and 123-126 in the β sheet.127 Using multivariate logistic regression 
analysis with a backward stepwise approach the AA positions most predictive (irrespective 
of the total number of AA differences) for negative CTLp assay were identified: position 62, 
63, 73, 80, 138, 144, 163 (α helices) and 116 (β sheet). From this algorithm a weighted AA 
mismatch score was derived and associated with a negative CTLp assay.
End points and competing risks
The primary endpoint of the study was time to ≥ grade II aGVHD. Peak severity of aGVHD 
after HSCT defined according to grade (no, I, II, III or IV) was available for 317 patients. 
Patients without aGVHD before day 100 were censored at date of donor lymphocyte 
infusion (DLI), relapse or second HSCT within 100 days after HSCT if applicable and at 
100 days after HSCT otherwise. Death without ≥ grade II aGVHD within 100 days after 
HSCT was treated as a competing risk. 
Secondary outcomes were mortality and relapse incidence. For 339 patients the 
cause of death was available. For the relapse analysis only the patients with malignant 
diseases (n=296) were included. Patients were censored at date of DLI or second HSCT 
and those who survived were censored at time of last contact. Looking at relapse, death 
without relapse was defined as competing risk. 
Statistical analysis
The AA mismatch score was divided into low, medium and high based on the distribution 
in the study population on which the algorithm was developed.158 We used only the low 
and high categories in order to get two distinct groups. The low score category was set 
as reference. The CTLp assay and AA mismatch score associated with HSCT outcome 
was investigated relative to 10/10 HLA matched HSCT.
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5Differences in patient, donor and HSCT characteristics between low and high AA 
mismatch scores and differences between 9/10 single HLA mismatched donor-recipient 
pairs with or without CTLp assay and 10/10 HLA matched donor-recipient pairs were 
examined with Pearson’s Chi square test or Fishers’ exact test for discrete variables 
and Kruskal-Wallis test for continuous variables. Hazard ratios (HR), 95% confidence 
intervals (95% CI) and p values were obtained using the proportional hazards model 
for the subdistribution of competing risks of Fine and Gray116 to quantify the influence 
of AA mismatch score and CTLp assay on cumulative incidence of mortality, ≥ grade II 
aGVHD and relapse. 
Patient, donor and HSCT characteristics associated with AA mismatch score or CTLp 
assay and HSCT end points were considered as potential confounding variables in our 
dataset. They were evaluated in both AA mismatch score, and CTLp assay analysis for 
each end point separately and identified as confounding variables when including them 
in the model (one by one), the crude association (β estimate) changed by >10%.
In mortality analyses patient age at HSCT (continuous), donor age at HSCT 
(continuous), HSCT year (continuous), T cell depletion (TCD) of the graft (y/n), Campath 
use (y/n), HSCT center (Erasmus MC, UMCU or LUMC), conditioning type (myeloablative/
reduced intensity), donor type (related/unrelated donor), DPB1 mismatch (1 or 2 allele 
GvH direction/no mismatch), mismatched HLA class I locus (HLA-A/-B-/-C) and CMV 
mismatch (negative donor to positive patient y/n) were investigated.
In aGVHD analyses patient age at HSCT (continuous), donor age at HSCT (continuous), 
HSCT year (continuous), TCD of the graft (y/n), Campath use (y/n), HSCT center (Erasmus 
MC, UMCU or LUMC), ATG use (y/n), graft type (PBSC/BM), donor type (related/unrelated 
donor), DPB1 mismatch (1 or 2 allele GvH direction/no mismatch), mismatched HLA 
class I locus (HLA-A/-B-/-C) and Ciclosporin use (y/n), were investigated. 
In relapse analyses patient age at HSCT (continuous), HSCT year (continuous), 
Campath use (y/n), HSCT center (Erasmus MC, UMCU or LUMC), conditioning type 
(myeloablative/reduced intensity), Ciclosporin use (y/n), ATG use (y/n), ABO mismatch 
(y/n), donor type (related/unrelated donor), DPB1 mismatch (1 or 2 allele GvH direction/
no mismatch), mismatched HLA class I locus (HLA-A/-B-/-C) and CMV mismatch 
(negative donor to positive patient y/n) were investigated. All identified confounding 
variables were included in the multivariate corrected models.
Two sided p-values ≤ .050 were considered statistically significant. Statistical 
analysis was performed using SPSS 19.0 for Windows (IBM) and the CMPRSK package 
in R (open source). 
RESULTS
Patient, donor and HSCT characteristics are listed in Table 1 (CTLp analysis) and 
Table 2 (low versus high AA mismatch score analysis). CTLp assays were more often 
performed for younger patients treated in Leiden, for on average older transplantations 
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Table 1. CTLp Assay: Patient/donor/HSCT characteristics
9/10 HLA MM  
without CTLp 
n=98
9/10 HLA MM 
with CTLp  
n=73
10/10 HLA 
Match
n=168
Total  
n=339
p 
value
Patient age at HSCT, median 
(range)*
33  
(<1 – 66)
22  
(1 – 64)
29  
(<1 – 64)
29  
(<1 – 66)
.085
Donor age at HSCT, median 
(range)*
37 
 (20 – 55)
38  
(8 – 67)
33  
(2 – 55)
36 
 (2 – 67)
.113
Year of HSCT, median  
(range)*
2004
(1988 – 2008)
2001
(1992 – 2008)
2004
(1987 – 2008)
2004
(1987 – 2008)
.000
HSCT Center, n (%)# .000
   Leiden 28 (29) 73 (100) 76 (45) 177 (52)
   Rotterdam 20 (20) 0 (0) 41 (24) 61 (18)
   Utrecht 50 (51) 0 (0) 51 (30) 101 (30)
Unrelated donor, n (%)+ 93 (95) 67 (92) 159 (95) 319 (94) .597
Female (D) to male (P),n (%)# 23 (24) 14 (19) 23 (14) 60 (18) .131
ABO mismatch, n (%)# 56 (57) 43 (60) 108 (66) 207 (62) .374
CMV negative (D) to positive (P), 
n (%)#
25 (26) 11 (15) 46 (28) 82 (24) .121
Diagnosis, n (%)+ .998
   Acute leukemia 43 (44) 31 (43) 75 (45) 149 (44)
   Chronic leukemia 13 (13) 12 (16) 24 (14) 49 (15)
   Lymphoma 10 (10) 5 (7) 12 (7) 27 (8)
   Plasma cell disorder 7 (7) 3 (4) 12 (7) 22 (7)
   MDS/MPS 14 (14) 12 (16) 25 (15) 51 (15)
   Bone marrow failure 6 (6) 6 (8) 12 (7) 24 (7)
   Inherited disorder 5 (5) 4 (6) 8 (5) 17 (5)
CR/CP/non-malignant at HSCT, 
n (%)#
52 (53) 31 (43) 79 (47) 162 (48) .375
ATG, n (%)# 69 (76) 2 (3) 114 (70) 185 (57) .000
Myeloablative conditioning,  
n (%)#
62 (63) 56 (80) 116 (70) 234 (70) .065
Ciclosporin, n (%)# 83 (89) 65 (97) 134 (81) 282 (87) .003
TCD, n (%)# 41 (42) 48 (67) 78 (47) 167 (50) .004
Campath, n (%)# 32 (36) 20 (28) 51 (32) 103 (32) .568
TBI, n (%)# 74 (76) 51 (71) 123 (73) 248 (73) .791
Bone marrow graft, n (%)# 47 (48) 46 (63) 88 (53) 181 (54) .142
DPB1 MM, n (%)# 54 (55) 57 (78) 98 (58) 209 (62) .000
Mismatched HLA locus,n (%)# .785
   HLA-A 33 (34) 27 (37) NA 60 (35)
   HLA-B 17 (17) 10 (14) NA 27 (16)
   HLA-C 48 (49) 36 (50) NA 84 (49)
NA: not applicable; *Kruskall-Wallis test; # Pearson’s Chi square test; +Fishers’ exact test.
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5and for donor-recipient pairs with more HLA-DPB1 mismatches. Use of ATG, type of 
conditioning, use of Ciclosporin and TCD were statistically different in the CTLp tested 
group compared to the other groups. Patients were similar with respect to all other 
variables (Table1). HLA-DPB1 mismatches were more often seen in 9/10 HLA mismatches 
with low AA mismatch scores and those with high AA mismatch scores were more often 
seen in HLA-C allele mismatches. All other variables were not statistically significant 
different between the two AA mismatch groups (Table 2). 
Table 2. AA mismatch score: Patient/donor/HSCT characteristics
Low score  
n=81
High score 
n=51
Total  
n=132 p value
Patient age at HSCT, median (range)* 32 (<1 – 65) 22 (1 – 66) 29 (<1 – 66) .190
Donor age at HSCT, median (range)* 37 (20 – 55) 38 (8 – 53) 37 (8 – 55) .487
Year of HSCT, median (range)* 2004
(1988 – 2008)
2003
(1989 – 2008)
2003
(1988 – 2008)
.561
HSCT Center, n (%)# .169
   Leiden 41 (51) 33 (65) 74 (56)
   Rotterdam 12 (15) 3 (6) 15 (11)
   Utrecht 28 (35) 15 (29) 43 (33)
Unrelated donor, n (%)+ 79 (98) 46 (90) 125 (95) .107
Female (D) to male (P),n (%)# 17 (21) 11 (22) 28 (21) .891
ABO mismatch, n (%)# 43 (53) 31 (61) 74 (56) .386
CMV negative (D) to positive (P), n (%)# 16 (20) 11 (22) 27 (21) .829
Diagnosis, n (%)+ .647
   Acute leukemia 37 (46) 24 (47) 61 (46)
   Chronic leukemia 9 (11) 9 (18) 18 (14)
   MDS/MPS 12 (15) 7 (14) 19 (14)
   Bone marrow failure 5 (6) 5 (10) 10 (8)
   Lymphoma 7 (9) 2 (4) 9 (7)
   Inherited disorder 5 (6) 3 (6) 8 (6)
   Plasma cell disorder 6 (7) 1 (2) 7 (5)
CR/CP/non-malignant at HSCT, n (%)# 40 (49) 20 (39) 60 (46) .253
ATG, n (%)# 35 (47) 21 (41) 56 (45) .499
Myeloablative conditioning, n (%)# 50 (63) 38 (76) 88 (68) .131
Ciclosporin, n (%)+ 71 (96) 44 (88) 115 (93) .155
TCD, n (%)# 36 (45) 30 (59) 66 (50) .123
Campath, n (%)# 21 (28) 17 (33) 38 (30) .554
TBI, n (%)# 58 (73) 41 (80) 99 (76) .305
Bone marrow graft, n (%)# 41 (51) 31 (61) 72 (55) .253
DPB1 mm, n (%)# 53 (86) 31 (72) 84 (80) .092
Mismatched HLA locus, n (%)+ .000
   HLA-A 36 (44) 14 (28) 50 (38)
   HLA-B 22 (27) 1 (2) 23 (17)
   HLA-C 23 (28) 36 (71) 9 (45)
*Mann-Whitney U test; # Pearson’s Chi square test; +Fishers’ exact test
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Patients transplanted with a 9/10 single HLA class I mismatched graft with a positive 
CTLp assay have statistically significant worse survival [HR (95% CI): 2.43 (1.24 – 4.74)] 
compared to those with a negative CTLp assay. Patients transplanted with a 10/10 
HLA matched graft have similar survival [HR (95% CI): 1.00 (0.53 – 1.89)] as patients 
transplanted with a 9/10 single HLA class I mismatched graft with a negative CTLp 
assay (Figure 1A and Table 3).
The results for aGVHD and relapse incidence were unexpected; patients transplanted 
with a 9/10 single HLA class I mismatched graft without CTLp assay had statistically 
significant less grade ≥2 aGVHD [HR (95% CI): 0.23 (0.08 – 0.62)] (Figure 1B and Table 3) 
and those with a positive CTLp assay had non-significantly more relapse [HR (95% CI): 
2.13 (0.81 – 5.59)] compared to those with a negative CTLp assay (Figure 1C and Table 3).
In all 9/10 HLA mismatched donor-recipient pairs the AA mismatch score did not 
statistically significant influence any HSCT end point of interest. We did observe a non-
Figure 1. Cumulative incidence of A 
mortality (lines for negative CTLp assay 
and matched HSCT overlap), B grade ≥II 
aGVHD and C relapse (lines for no CTLp 
assay and matched HSCT overlap) for 
9/10 HLA mismatched donor-recipient 
pairs with negative, positive or no CTLp 
assay and 10/10 HLA matched pairs. See 
for statistics Table 3.
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5Table 3. Association between CTLp assay, AA mismatch score and HSCT outcome
Mortality n
Crude associations
(univariate analysis)
Corrected associations
(multivariate analysis)
CTLp analysis 339 HR (95% CI) p value HR (95% CI)* p value
CTLp negative 40 1.00 (ref) 1.00 (ref)
CTLp positive 33 2.77 (1.53 – 5.02) .00079 2.43 (1.24 – 4.74) .009
Mismatched No CTLp 98 1.51 (0.89 – 2.55) .120 1.52 (0.76 – 3.07) .240
Matched 168 0.98 (0.59 – 1.63) .950 1.00 (0.53 – 1.89) 1.00
Score analysis 300
Low Score 81 1.00 (ref) 1.00 (ref)
High Score 51 1.03 (0.67 – 1.58) .910 0.92 (0.57 – 1.48) .730
Matched 168 0.65 (0.47 – 0.89) .007 0.64 (0.46 – 0.89) .007
aGVHD n
Crude associations
(univariate analysis)
Corrected associations
(multivariate analysis)
CTLp analysis 317 HR (95% CI) p value HR (95% CI)+ p value
CTLp negative 40 1.00 (ref) 1.00 (ref)
CTLp positive 33 0.78 (0.34 – 1.82) .570 0.67 (0.26 – 1.74) .410
Mismatched No CTLp 85 0.59 (0.29 – 1.21) .150 0.23 (0.08 – 0.62) .003
Matched 159 0.47 (0.25 – 0.90) .023 0.18 (0.06 – 0.52) .001
Score analysis 278
Low Score 71 1.00 (ref) 1.00 (ref)
High Score 48 1.39 (0.74 – 2.61) .300 1.48 (0.80 – 2.72) .210
Match 159 0.73 (0.43 – 1.25) .250 0.65 (0.36 – 1.19) .160
Relapse n
Crude associations
(univariate analysis)
Corrected associations
(multivariate analysis)
CTLp analysis 296 HR (95% CI) p value HR (95% CI)^ p value
CTLp negative 33 1.00 (ref) 1.00 (ref)
CTLp positive 29 1.97 (0.82 – 4.72) .130 2.13 (0.81 – 5.59) .130
Mismatched No CTLp 86 1.19 (0.57 – 2.49) .640 0.88 (0.33 – 2.34) .790
Matched 148 1.21 (0.60 – 2.41) .600 0.90 (0.36 – 2.26) .820
Score analysis 260
Low Score 70 1.00 (ref) 1.00 (ref)
High Score 42 1.43 (0.57 – 3.56) .440 1.46 (0.52 – 4.10) .480
Match 148 1.00 (0.54 – 1.85) .990 0.80 (0.32 – 1.99) .640
*Mortality models corrected for: age patient at HSCT, age donor at HSCT, HSCT year, TCD of the graft, 
Campath use, HSCT center and conditioning type. #aGVHD models corrected for: age patient at HSCT, 
age donor at HSCT, HSCT year, TCD of the graft, Campath use, HSCT center, ATG use and graft type. 
+Relapse models corrected for: age patient at HSCT, HSCT year, Campath use, HSCT center, conditioning 
type, Ciclosporin use, ATG use, ABO mismatch and CMV mismatch. 
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significant increased incidence of grade ≥2 aGVHD in the high AA mismatch score 
group [HR (95% CI): 1.48 (0.80 – 2.72)] (Figure 2B and Table 3) and a non-significant 
increased incidence of relapse in the high AA mismatch score group [HR (95% CI): 1.46 
(0.52 – 4.10)] (Figure 3C and Table 3).
DISCUSSION
We studied the association between the AA mismatch score and clinical outcome for 
patients transplanted with a 9/10 HLA class I mismatched graft. We expected a high 
AA mismatch score to be associated with a low incidence of mortality (or aGVHD). 
Because previously we observed that a high AA mismatch score is associated with a 
negative CTLp assay and a negative CTLp assay itself is associated with low incidence of 
mortality (or aGVHD). Additionally we verified the clinical relevance of the CTLp assay.
Figure 2. Cumulative incidence of A 
mortality, B grade ≥II aGVHD and C 
relapse (lines for low AA mismatch score 
and matched HSCT overlap) for 9/10 
HLA mismatched donor-recipient pairs 
with low and high AA mismatch score 
and 10/10 HLA matched pairs. See for 
statistics Table 3.
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5The present report confirms that a negative CTLp assay for 9/10 HLA class I 
mismatched donor-recipient pairs is associated with a decreased incidence of mortality 
after HSCT, comparable to that of 10/10 HLA matched HSCT, consistent with previous 
results form our group37 but also from others.130,131 Although it is possible to predict 
negative CTLp assay with our algorithm158, we did not observe a similar decrease in 
mortality incidence with the AA mismatch score, nor did we see a clear association 
with aGVHD or relapse. The association between a negative CTLp assay and decreased 
mortality incidence itself is an important observation, the responsible mechanism is 
unclear. Especially given that donor-recipient pairs with a negative CTLp assay do not 
seem to have decreased incidence of aGVHD in our population, which would be expected 
if a negative CTLp assay implies an absence of patient specific CTL allorecognition 
in vivo.5,6 Others did find decreased aGVHD associated with negative or low levels of 
host CTL precursors.129,130,132-134 Instead we observed a higher incidence of ≥ grade II 
aGVHD and a higher incidence of relapse, although both non-significant. The decrease 
in mortality in the negative CTLp mismatches may not be a direct consequence of 
a lower incidence of aGVHD. The absence of donor specific CTLs may be indirectly 
associated with a more efficient recognition of infections, minor histocompatibility 
antigens (mHags) and/or leukemic cells.
Many other factors could have confounded our results because a number of 
variables were differentially distributed in the CTLp assay groups. Although a number 
of parameters could have been responsible for the favorable HSCT outcome in the 
negative CTLp assay group (younger patients, more use of Ciclosporin, more TCD, 
more use of BM grafts), other factors would more likely increase incidence of mortality 
(older transplants, less use of ATG, more myeloablative conditioning, more HLA-DPB1 
mismatches). We believe most of these differences are rather a reflection of different 
policies at HSCT centers than associated with the CTLp assay itself. The CTLp assay is not 
performed routinely, but has a clinical indication and it is unlikely that donor-recipient 
pairs with a CTLp assay are selected on phenotype. All above mentioned variables 
were tested in different multivariate models to correct for confounding. HLA-DPB1 
mismatching and HLA mismatched allele were not identified as confounding factors in 
our data and therefore not included in any model. 
Also, killer cell immunoglobulin like receptors (KIR) mismatching could theoretically 
influence outcome of the CTLp assay. Of the 171 single HLA class I mismatched donor-
recipient pairs, 20 had a KIR ligand mismatch (KIR2DL1, KIR2DL2/3, KIR3DL1 or KIR3DL2) 
in the GvH direction. KIR ligand mismatching was associated with neither negative CTLp 
assay, nor with AA mismatch score nor with HSCT outcome (data not shown).
The decreased mortality rate seen for donor-recipient pairs with a negative CTLp assay 
is not observed in the AA mismatch score analyses. Therefore, the present algorithm 
does not correctly predict the 9/10 HLA class I mismatches which are clinically relevant. 
It may well be that a functional CTLp assay in vitro reflects parameters which are crucial 
for mortality after HSCT but which can not be fully predicted by the AA sequence of 
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HLA molecules alone. It may be possible that a negative CTLp assay does not indicate 
the absence of direct CTL allorecognition of the mismatched HLA class I antigen, but 
rather an induced state of tolerance. A number of aspects can induce tolerance or cause 
CTL recognition which may be different in each individual donor-recipient pair. Indirect 
presentation of mHags, peptides derived from the mismatched HLA molecule or HLA 
class II molecules in one of the shared HLA molecules could be responsible. Our CTLp 
assay measures the immune response before HSCT, mainly based on direct recognition 
of the mismatched HLA class I antigen and therefore high AA scores (large/more AA 
differences) predict absence of direct allorecognition. After HSCT the presence of more 
AA differences is more likely to be associated with indirect allorecognition and antibody 
formation causing the discrepancy between in vitro and in vivo results.
Further investigation is needed to unravel the mechanisms involved in CTL 
alloreactivity, both in vitro and in vivo, before we may develop a reliable tool to predict 
HSCT outcome.
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ABSTRACT
To predict humoral alloreactivity, the transplantation group in Cambridge extended 
HLAMatchmaker by taking the hydrophobic and electrostatic disparities (HMS and 
EMS) of the amino acids (AAs) in the mismatched HLA class I molecule into account. We 
wondered whether HMS/EMS may be of additional value to predict cellular alloreactivity 
in hematopoietic stem cell transplantation (HSCT). We selected 171 patients 
transplanted with a 9/10 single HLA class I mismatched graft and as controls 168 10/10 
HLA-A, -B, -C, -DRB1, -DQB1 matched donor-recipient pairs. To study HMS/EMS in 
relation to cytotoxic T lymphocyte precursor (CTLp) frequency, 131 9/10 single HLA-A 
or -C mismatched donor-recipient pairs were selected. The Cambridge algorithm was 
adjusted for prediction of cellular allorecognition, considering AA positions important 
in T cell receptor (TCR) recognition and/or peptide binding. Donor-recipient pairs with 
high EMS have increased incidence of ≥ grade II aGVHD compared to pairs with low 
EMS [HR (95% CI): 2.60 (1.01 – 6.71)]. Contrarily, increasing EMS/HMS scores [high EMS, 
OR (95% CI): 3.30 (1.31 – 8.30)] are associated with a negative CTLp assay. These results 
confirm that cellular and humoral alloimmune responses are different in vitro, but it 
appears that they are more similar in vivo.
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6INTRODUCTION
Attempts have been made to reliably predict cytotoxic T cell (CTL) alloreactivity and 
hematopoietic stem cell transplantation outcome (HSCT) from the amino acid (AA) 
sequence of human leukocyte antigen (HLA) molecules. Our group40,140 and others41,42 
showed that tools like HLAMatchmaker159 and Histocheck141 are not suitable to predict CTL 
alloreactivity. HLAMatchmaker was initially developed for determining HLA compatibility 
by predicting humoral alloresponses from the number of antibody accessible triplet 
differences in mismatched HLA molecules. In the setting of organ transplantation it is 
proven to be an effective tool160 in contrast to HSCT where it is not.39 The transplantation 
group in Cambridge took a slightly different approach in predicting humoral 
alloreactivity, extending the HLAMatchmaker point of view, by also taking into account 
the physicochemical properties [hydrophobic mismatch score (HMS) and electrostatic 
mismatch score (EMS)] of the AAs in the mismatched HLA class I and class II molecules.145,161 
We recently proposed an algorithm predictive for CTL alloreactivity (CTLp assay in vitro) 
in single HLA class I mismatched donor-recipient pairs158 focusing on number, position 
and compatibility of AA differences in the α1/α2 domain of the HLA molecule. In this 
algorithm we assumed that not every AA in the structure of an HLA molecule will have 
similar effects on CTL alloreactivity, resulting in a weighted AA mismatch score. Mismatches 
with a high AA mismatch score are associated with negative CTL alloreactivity in vitro, 
which is opposite from what is observed in humoral alloreactivity where higher disparity 
(i.e. more triplet or AA differences) is associated with positive antibody responses. We 
wondered whether the HMS and/or EMS developed in Cambridge may be of additional 
value to predict CTL alloreactivity and HSCT outcome. Following previous observations, 
we hypothesize that high HMS and/or EMS will be associated with lower levels of CTL 
alloreactivity.37,127,158 If so, then we would also expect to see a difference in HSCT outcome.
PATIENTS AND METHODS
Donor-recipient pairs
To study HMS/EMS in relation to the CTLp assay, 131 9/10 single HLA-A or -C mismatched 
consecutive donor-recipient pairs with successful CTLp assays were selected. The 
CTLp assays were performed between 1988 and 2008. All donor-recipient pairs were 
compatible for HLA-B, -DRB1 and -DQB1. The specific HLA mismatches and detailed 
information on the study population was published previously.162
Not all donor-recipient pairs with a CTLp assays were eventually transplanted. To 
have a sufficient number of donor-recipients pairs to study HMS/EMS in relation to 
HSCT outcome we selected all patients who were transplanted with a 9/10 single HLA 
class I mismatched graft (n=171) in three HSCT centers the Netherlands [(Erasmus 
Medical Center (MC), University Medical Center Utrecht (UMCU) and Leiden University 
Medical Center (LUMC)]. As controls we selected 168 10/10 HLA-A, -B, -C, -DRB1, 
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-DQB1 matched donor-recipient pairs matched for HSCT year, donor type, patient age 
and diagnosis to the 9/10 single HLA class I mismatched pairs (total cohort: n=339). The 
study population include pediatric (n=112) and adult patients (n=227) with malignant 
(n-296) and non-malignant (n=41) diseases. Donors originated from national or 
international donor registries, 20 were family donors. Clinical patient information was 
made available by the HOVON Data Center through the European group for Blood and 
Marrow Transplantation (EBMT) patient database. 
HLA genotyping, AA sequencing and physicochemical properties
All donors and patients were typed at allele level for HLA-A, -B, -C, -DRB1, -DQB1 
as described previously125. Briefly, polymerase chain reaction sequence specific primer 
(PCR-SSP) for high resolution allele typing and sequence based typing (SBT), for part of 
the HLA-C alleles, were used. 
AA sequence comparisons between mismatched HLA class I specificities were 
performed using a previously described computer program.145 Initially, the program 
was developed to identify the position and nature of all disparate AAs in the entire 
α1/α2 domain. Conformational location of each disparate AA was considered 
according to whether or not they were positioned in an antibody accessible region of 
the HLA molecule. For the purposes of this study, focusing on cellular allorecognition, 
the program was adjusted to enable separate consideration of AA residues that are 
important in TCR recognition and/or peptide binding. Accordingly, AA at positions 
49-85 and 137-180 in the α helices were considered important for TCR contact and 
residues at positions 3-13, 21-29, 31-38, 46-48, 93-104, 108-119, 121-127 and 132-136 
in the β sheets were considered important for peptide binding.33,34,127,136
As previously described, each AA was assigned a hydrophobicity value using the 
Hopp-Woods scale163 and a hydrophobicity mismatch value was determined as the 
difference in AA hydrophobicity values. Similarly, the difference between the isoelectric 
points (pI) of each mismatched AA was determined. For each mismatched HLA class I 
specificity, the AA hydrophobicity and pI mismatched values were summed to give a total 
hydrophobicity mismatch score (HMS) and a total electrostatic mismatch score (EMS).145
CTLp assay
As an intermediate clinical readout the CTLp assay is routinely performed in our center 
to determine CTL alloreactivity in single HLA class I mismatched donor-recipient pairs. 
The CTLp assays were performed as described by Zhang et al36, with minor modifications 
as described by Oudshoorn et al125. CTLp assays were performed in the graft-versus-
host (GvH) direction. A negative CTLp assay was defined as ≤ 1 recipient specific CTL 
per 106 peripheral blood lymphocytes.
End points and competing risks
Primary endpoint for the HSCT analysis was incidence of ≥ grade II aGVHD. Peak severity 
of aGVHD after HSCT defined according to grade (no, I, II, III or IV) was available for 317 
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6patients. Patients were censored at date of DLI, relapse or second HSCT within 100 days 
after HSCT and at 100 days after HSCT. Death without ≥ grade II aGVHD within 100 days 
after HSCT was treated as a competing risk. 
Secondary outcomes in the HSCT analysis were relapse and mortality incidence. 
For 339 patients the cause of death was available and for the relapse analysis only the 
patients with malignant diseases (n=296) are included. Patients were censored at date 
of DLI or second HSCT and those who survived were censored at time of last contact. 
Looking at relapse, death without relapse was defined as competing risk. 
Statistical analysis
For the single 9/10 HLA class I mismatched grafts, the number of AA differences, EMS 
and HMS variables (calculated for the entire α1/α2 domains and separately for the TCR/
peptide contact residues in the α helices + β sheets) were divided into 3 or 4 groups 
(tertiles or quartiles) based on their distribution. The lowest tertile or quartile was set 
as reference category. We chose to use tertiles and quartiles to ensure objectivity and 
even sized categories.
Association between EMS/HMS of single 9/10 HLA class I mismatches and HSCT 
outcome was investigated relative to 10/10 HLA matched HSCT. Differences in patient-, 
donor- and HSCT characteristics between low, medium and high EMS/HMS were 
examined with Pearson’s Chi square test or Fishers’ exact test for discrete variables 
and Kruskal-Wallis test for continuous variables. Hazard ratios (HR), 95% confidence 
intervals (95% CI) and p values were obtained using the proportional hazards model for 
the subdistribution of competing risks of Fine and Gray116 to quantify the association 
between EMS/HMS and cumulative incidence of ≥ grade II aGVHD, relapse and mortality.
Patient, donor and HSCT characteristics that were associated with EMS or HMS and 
HSCT end points were considered as potential confounding variables in our dataset. 
They were evaluated for each end point separately and identified as confounding 
variables when including them in the model (one by one), the crude association (β 
estimate) changed by >10%.
For aGVHD models HSCT center (Erasmus MC, UMCU or LUMC), mismatched locus 
(HLA-A, -B, or -C), HSCT year (continuous), patient age at HSCT (continuous), donor age 
at HSCT (continuous), Ciclosporin use (y/n), Campath use (y/n), TCD of the graft (y/n) 
and conditioning type (myeloablative/reduced intensity) were considered. For relapse 
models HSCT center (Erasmus MC, UMCU or LUMC), mismatched locus (HLA-A, -B, or -C), 
patient age at HSCT (continuous), TCD of the graft (y/n), TBI part of the conditioning 
(y/n), donor age at HSCT (continuous) and conditioning type (myeloablative/reduced 
intensity) were considered. For mortality models mismatched locus (HLA-A, -B, or -C), 
patient age at HSCT (continuous), TCD of the graft (y/n), Ciclosporin use (y/n), donor age 
at HSCT (continuous), HSCT year (continuous),  and conditioning type (myeloablative/
reduced intensity) were considered. All identified confounding variables were included 
in the multivariate models.
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Next, association of number of AA differences and levels of EMS/HMS (calculated 
for the entire α1/α2 domain and separately for the TCR/peptide contact residues in 
the α helices + β sheets) and the probability of a negative CTLp assay was evaluated 
with Pearson’s Chi square test. In addition odds ratios (OR), 95% confidence intervals 
(95% CI) and p values were obtained using logistic regression analysis to quantify these 
associations. To correct for the number of AA mismatches, multivariate analysis was 
performed forcing the total number of AA mismatches into the model.
Two sided p-values ≤ .050 were considered statistically significant. Statistical 
analysis was performed using SPSS 19.0 for Windows (IBM) and the CMPRSK package 
in R (open source). 
RESULTS
Donor-recipient pairs with high EMS showed a statistically significant increase in cumulative 
incidence of ≥ grade II aGVHD compared to pairs with low EMS in multivariate analysis [HR 
(95% CI): 2.60 (1.01 – 6.71)]. Of patients transplanted with 9/10 single HLA mismatched 
grafts, those with low EMS had similar aGVHD incidence to patients transplanted with 
10/10 HLA matched grafts (Table 2 and Figure 1A). Patients transplanted with a 10/10 
HLA matched graft had superior survival compared to patients transplanted with a 9/10 
single HLA mismatched graft and no difference was observed in cumulative incidence of 
mortality between the three EMS groups (Table 2 and Figure 1C). Finally, the cumulative 
incidence of relapse was similar for all patients, independent of EMS and HLA mismatch 
grade (Table 2 and Figure 1B). Patients with low, medium and high EMS scores were similar 
with respect to all patient, donor and HSCT characteristics examined (Table 1). When 
the impact of HMS was considered, similar results were obtained (data not shown) with 
no independent effect of HMS over EMS. Similarly, when the physiochemical disparity 
(EMS/HMS) of single HLA mismatched grafts was calculated based on AA differences 
located in TCR/peptide contact positions in the α helices and β sheets the relationship 
with incidence of aGVHD remained significant (data not shown).
Of 131 donor-recipient pairs with 9/10 single HLA mismatched grafts that had successful 
CTLp assays, 78 (59%) had a positive and 53 (41%) a negative CTLp assay. As shown 
previously158, increasing number of AA differences in the α helices (TCR contact) and β sheets 
(peptide binding) were associated with a negative CTLp assay [Table 3, highest category: 
OR (95% CI): 3.32 (1.31-8.45)], but this association was not evident when AA differences in 
the entire α1 and α2 domains were considered. Moreover, increasing HLA physiochemical 
disparity (high EMS/HMS) was associated with higher likelihood for a negative CTLp assay 
and this relationship was present when either the entire α1 and α2 domains or the specific 
residues in the α helices and β sheets only were examined (Table 3 and Figure 2 and 3). 
However, the association between EMS/HMS and the CTLp assay for single 9/10 HLA 
mismatched grafts was less strong following correction for the number of AA mismatches, 
likely reflecting the relatively small numbers of patients included in this study (Table 3).
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6Table 1. Patient/donor/HSCT characteristics
Low EMS
n=60
Medium EMS
n=56
High EMS
n=55
Total
n=171 p value
Patient age at HSCT,
median (range)*
33  
(<1 – 64)
23  
(1 – 66)
33  
(1 – 66)
29  
(>1 – 66)
.541+
Donor age at HSCT,
median (range)*
35  
(20 – 55)
38  
(23 – 63)
38  
(8 – 67)
37  
(8 – 67)
.308+
Year of HSCT,
median (range)*
2003
(1988 – 2008)
2003
(1989 – 2008)
2004
(1992 – 2008)
2003
(1988 – 2008)
.723+
Unrelated donor, n(%)+ 58 (97) 53 (95) 48 (87) 159 (93) .113#
HSCT Center, n (%)# .490*
   Leiden 31 (52) 35 (63) 35 (64) 101 (59)
   Rotterdam 9 (16) 4 (7) 7 (13) 20 (12)
   Utrecht 20 (33) 17 (30) 13 (24) 50 (29)
DPB1 mismatch GVH,n (%)# 40 (87) 34 (74) 37 (79) 111 (80) .288*
Female (D) to male (P), n (%)# 13 (22) 12 (21) 12 (22) 37 (22) .995*
ABO mismatch, n (%)# 33 (55) 35 (63) 31 (57) 99 (58) .707*
CMV negative (D) to positive (P),  
n (%)#
14 (24) 13 (23) 9 (16) 36 (21) .568*
Diagnosis, n (%)+ .594#
   Acute leukemia 29 (48) 19 (34) 26 (47) 74 (43)
   Chronic leukemia 7 (12) 11 (20) 7 (13) 25 (15)
   Plasma cell disorder 3 (5) 5 (9) 2 (4) 10 (6)
   MDS/MPS 11 (18) 8 (14) 7 (13) 26 (15)
   Bone marrow failure 3 (5) 3 (5) 6 (11) 12 (7)
   Inherited disorder 3 (5) 5 (9) 1 (2) 9 (5)
   Lymphoma 4 (7) 5 (9) 6 (11) 15 (9)
Disease type, n (%)# .926*
   Myeloid malignancy 35 (58) 30 (55) 28 (52) 93 (55)
   Lymphoid malignancy 19 (32) 17 (31) 19 (35) 55 (33)
   Non- malignant 6 (10) 8 (15) 7 (13) 21 (12)
ATG, n (%)* 27 (47) 23 (44) 21 (40) 71 (44) .758*
Myeloablative conditioning,  
n (%)*
40 (69) 40 (73) 38 (70) 118 (70) .886*
Ciclosporin, n (%)+ 56 (97) 43 (88) 49 (93) 148 (93) .227#
TCD, n (%)# 27 (46) 33 (59) 29 (54) 89 (53) .362*
Campath, n (%)# 14 (25) 18 (35) 20 (38) 53 (32) .300*
TBI, n (%)# 42 (73) 38 (68) 45 (82) 125 (74) .219*
CR/CP/non-malignant at HSCT, 
n (%)#
29 (48) 32 (57) 27 (49) 88 (52) .582*
Bone marrow graft, n (%)# 32 (53) 32 (57) 29 (53) 93 (54) .878*
EMS: electrostatic mismatch score; analyses with HMS (hydrophobic mismatch score) gave similar 
results (data not shown); *Kruskall-Wallis test; # Pearson’s Chi Square test; +Fishers’ exact test.
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Figure 1. EMS (entire α1/α2 domain) in 
association with cumulative incidence 
of A grade ≥II aGVHD, B relapse and 
C mortality. See for statistics Table 2. 
Analysis with HMS gave similar results 
(data not shown)
Figure 2. AA differences in A α1/α2 domain (χ2=4.186, p= .123) and B α helices + β sheet (χ2=7.065, 
p= .029) in association with negative CTLp assay. See for statistics Table 3.
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6Table 2. EMS in association with HSCT outcome
n
Crude associations  
(univariate analysis)
Corrected associations 
(multivariate analysis)
≥ grade II aGVHD 317 HR (95% CI) p value HR (95% CI)# p value
Low EMS 55 1.00 (ref) 1.00 (ref)
Medium EMS 49 1.28 (0.55 – 2.99) .560 1.67 (0.61 4.59) .320
High EMS 54 1.90 (0.87 – 4.17) .110 2.60 (1.01 – 6.71) .048
10/10 HLA matched 159 0.91 (0.44 – 1.88) .790 1.00 (0.36 – 2.79) .990
Relapse 296 HR (95% CI) p value HR (95% CI)+ p value
Low EMS 54 1.00 (ref) 1.00 (ref)
Medium EMS 47 1.41 (0.70 – 2.82) .330 1.65 (0.64 – 4.28) .300
High EMS 47 0.87 (0.42 – 1.81) .710 0.94 (0.36 – 2.46) .900
10/10 HLA matched 149 1.03 (0.58 – 1.84) .930 1.00 (0.39 – 2.58) 1.00
Mortality 339 HR (95% CI) p value HR (95% CI)* p value
Low EMS 60 1.00 (ref) 1.00 (ref)
Medium EMS 54 1.10 (0.68 – 1.78) .710 1.03 (0.58 – 1.80) .930
High EMS 57 0.93 (0.58 – 1.50) .770 0.79 (0.44 – 1.41) .430
10/10 HLA matched 168 0.64 (0.43 – 0.96) .030 0.53 (0.31 – 0.91) .022
EMS: electrostatic mismatch score; analyses with HMS (hydrophobic mismatch score) gave similar 
results (data not shown); *Mortality model corrected for: mismatched locus, patient age at HSCT, use 
of Ciclosporin, donor age at HSCT, conditioning type; #aGVHD model corrected for: HSCT center, 
mismatched locus, patient age at HSCT, use of Campath, conditioning type; +Relapse model corrected 
for: HSCT center, mismatched locus, TBI part of the conditioning, donor age at HSCT, conditioning type
DISCUSSION
The most important finding in this report is the association between high EMS and 
an increased probability of incidence of aGVHD. Similar to what is seen in organ 
transplantation these results suggest that high HLA disparity defined at the AA 
sequence level results in deteriorated HSCT outcome.164 Secondly, we observe that high 
EMS is associated with an increased probability of a negative CTLp assay for 9/10 HLA 
class I mismatched donor-recipient pairs. This observation is opposite from what is 
seen for humoral alloreactivity, where increasing physicochemical disparity is positively 
associated with an antibody response.145 These results confirm once more the fact that 
cellular and humoral alloimmune responses are different in vitro, but it appears that 
they are more similar in vivo.
The CTLp assay is a function of direct allorecognition and therefore high EMS scores 
and high AA mismatches reflect molecular disparity leading to defective ‘self restriction’ 
associated with a negative assay. However, aGVHD is a more composite outcome and 
relates to both direct and indirect responses at the GvH direction, perhaps similar to a 
conventional immunogenic response at the host versus graft (HvG) direction observed 
in solid organ transplantation. 
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We observe no association between EMS/HMS and incidence of relapse or mortality, 
although a negative CTLp assay for 9/10 HLA class I mismatched donor-recipient pairs 
is associated with a decreased incidence of mortality after HSCT, comparable to that 
of 10/10 HLA matched HSCT.162 Probable explanation may be that in direct recognition 
large physicochemical or AA differences results in no alloreaction and in indirect 
recognition very different peptides result in high alloresponses.  
Mismatching for a single HLA-DRB1 is associated with increased incidence of 
aGVHD and mismatching at HLA-DQB1 in the presence of mismatches at other loci 
(HLA-A, -C, -B or -DRB) is associated with a small  increased risk of mortality.26 To avoid 
confounding all donor-recipient pairs in this analysis were matched for HLA-DRB1 and 
-DQB1. Subsequently, mismatching for HLA-DPB1 is also associated with increased risk 
of aGVHD.25 Additional matching of our donor-recipient pairs for HLA-DPB1 was not 
Figure 3. EMS in A α1/α2 domain (χ2=8.671, p= .034) and B α helices + β sheet (χ2=7.555, p= .056) 
in association with negative CTLp assay. See for statistics Table 3.
Figure 4. HMS in A α1/α2 domain (χ2=8.792, p= .032) and B α helices + β sheet (χ2=8.470, p= .037) 
in association with negative CTLp assay. See for statistics Table 3.
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6possible. Only 15-20% of 10/10 HLA matched pairs are also matched at the HLA-DPB1 
locus because of weak linkage disequilibrium (LD) between HLA-DPB1 and the rest 
of the MHC. However, we observed no difference in HLA-DPB1 mismatches between 
donor-recipient pairs with high, medium and low EMS/HMS. Also, the total number 
of AA differences between donor and recipient was not found to be associated with 
any HSCT end point nor was it identified as a confounding factor. Therefore total 
number of AA differences was not included in any multivariate model. Furthermore, no 
Table 3. AA, EMS and HMS in association with negative CTLp assay
n (%)
Crude associations
(univariate analysis)
Corrected associations
(multivariate analysis)
AA α1/α2 domain
1 – 9 43 (33) 1.00 (ref) .129 (overall) NA
10 – 14 45 (34) 2.26 (0.93 – 5.49) .072
16 – 25 43 (33) 2.25 (0.92 – 5.50) .077
AA α helices + β sheet
1 – 6 49 (37) 1.00 (ref) .033 (overall) NA
7 – 9 49 (37) 2.26 (0.97 – 5.27) .060
10 – 16 33 (25) 3.32 (1.31 – 8.45) .012
EMS α1/α2 domain
0.18 – 15.02 33 (25) 1.00 (ref) .047 (overall) 1.00 (ref) .208 (overall)
15.28 – 25.15 35 (27) 3.42 (1.12 – 10.45) .031 4.05 (0.95 – 17.27) .059
25.56 – 35.34 31 (23) 4.60 (1.50 – 14.11) .008 6.12 (1.12 – 33.34) .036
36.41 – 58.54 32 (25) 3.82 (1.24 – 11.80) .020 5.65 (0.84 – 37.99) .075
EMS α helices + β sheet
0.18 – 13.42 33 (25) 1.00 (ref) .069 (overall) 1.00 (ref) .271 (overall)
14.04 – 24.11 37 (28) 2.83 (0.98 – 8.15) .054 3.23 (0.79 – 13.26) .104
24.13 – 31.36 29 (22) 3.02 (1.00 – 9.16) .051 3.71 (0.74 – 18.68) .112
31.85 – 57.10 32 (24) 4.21 (1.42 – 12.47) .009 5.65 (1.01 – 31.68) .049
HMS α1/α2 domain
0.20 – 14.19 33 (25) 1.00 (ref) .040 (overall) 1.00 (ref) .108 (overall)
14.90 – 27.69 32 (25) 2.23 (0.74 – 6.69) .153 3.10 (0.73 – 13.21) .127
27.80 – 35.90 33 (25) 3.50 (1.19 – 10.28) .023 6.17 (0.97 – 39.39) .054
36.70 – 56.20 33 (25) 4.46 (1.51 – 13.12) .007 14.24 (1.70 – 119.15) .007
HMS α helices + β sheet
0.20 – 13.30 33 (25) 1.00 (ref) .046 (overall) 1.00 (ref) .202 (overall)
13.59 – 24.49 34 (26) 2.30 (0.78 – 6.80) .132 2.89 (0.69 – 12.04) .145
24.69 – 29.29 36 (28) 4.15 (1.44 – 11.99) .009 5.59 (1.10 – 28.36) .038
30.99 – 55.20 28 (21) 3.71 (1.22 – 11.34) .021 5.11 (0.88 – 29.67) .069
EMS: electrostatic mismatch score; HMS: hydrophobic mismatch score; NA: not applicable; multivariate 
models are corrected for the total number of AA mismatches.
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other factors were differentially distributed between donor-recipient pairs with high, 
medium and low EMS/HMS. 
We did check every variable for every end point separately and see if they influenced 
HSCT outcome in our study population. Factors that were found to be associated with 
aGVHD, relapse and/or mortality (Table 2) were included in the multivariate model to 
correct for confounding. The change in the estimates were minor and therefore we 
believe confounding did not play a major role in our analysis.
A major strength of our survival analysis is that we used competing risk analysis in 
both UD search and HSCT analysis preventing overestimated estimates.
Consistent with previous observations127,158, we see a stronger association between 
number of AA mismatches and CTLp assay when considering only the number of AA 
differences in the α helices and β sheet rather than positions in the whole α1/α2 domain. 
Considering EMS/HMS we do not see this difference in position, possibly because 
large physicochemical differences affect conformation in such a way that the position 
in the α1/α2 domain is less important. In contrast to position of the AAs, the total 
number of AA differences seems to be more important because after adjustment for 
total number of AA differences the association between EMS/HMS and negative CTLp 
assay was less evident. None of the observed associations between AA/EMS/HMS 
and CTLp assay are absolute. The number of AA differences and EMS/HMS are not 
exclusively responsible for a negative CTLp assay. Possibly a negative CTLp assay does 
not only reflect an absence of the possibility for direct T cell allorecognition of the 
mismatched HLA class I antigen, but an induced state of tolerance to HLA antigens 
which can be recognized. Additionally, non inherited maternal antigens150, mHags165 
and/or viral specific crossreactivity151 may be expected to play a role in the CTLp assay.
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7ACCESS TO HSCT
Setting up and executing a research plan to investigate access to hematopoietic stem 
cell transplantation (HSCT) for adult patients in need of an HSCT proved to be a bigger 
challenge than we anticipated on. Determining the absolute number of patients in need 
of an HSCT was not possible due to two factors. First there is no obligatory (cancer) 
registration for adults in the Netherlands and second there are no strict national 
guidelines defining which patients are eligible for HSCT and which are not. Due to 
these difficulties and a certain level of resistance from professionals in the HSCT field 
we decided to focus our research on pediatric patients.
For pediatric patients there is obligatory registration at the Dutch childhood 
oncology group (DCOG) and there are national treatment protocols available which 
are much stricter compared to those for adult patients. In chapter 2, we identified a 
population (n=165) of patients with myelodysplastic syndrome (MDS) and relapsed 
acute myeloid leukemia (AML) as patients eligible for HSCT. For 95% of these patients 
an unrelated HSCT is available. In 5% of the cases it might be questionable why no 
unrelated donor (UD) search was initiated. So although we were not able to study this 
issue in an adult population we did get information from the DCOG about decisions 
made before and during the UD search for pediatric patients. Most pediatric patient 
with MDS and relapsed AML are offered an HSCT, which is an encouraging finding.
Clinical implications
The limit for an acceptable length of time between diagnosis and date of death or last 
follow up for no UD search to start is arbitrarily chosen. Therefore the 5% of patients 
who did not have access is not a definite percentage and might be subject to discussion 
depending on circumstances for each specific patient. However, we were unaware of 
the circumstances and/or the condition of the patients to make further judgments. In 
this way we could maintain objectivity and treat all cases in the same way.
Comparing our results to results from other countries points out the high level of 
access to HSCT in the Netherlands, for this specific group of pediatric patients. We can 
only speculate about the reasons that most children with MDS or relapse AML have access 
to HSCT, but these findings suggest the importance of a reliable registration system and 
detailed eligibility description in treatment protocols which are followed nationally.
On the other hand it is important to stay aware of reasons why HSCT was not 
offered as a potential therapy to eligible patients. Poor clinical condition may be the 
major reason to omit an UD search. It is difficult to determine what the optimal moment 
is to proceed to HSCT, but strictly looking at the time intervals regardless of whatever 
happened in a later time point, the eight patients (5%) should have had access to 
HSCT. Therefore early referral still needs to be encouraged. By publishing these results 
we hope to bring the issues of equal access to treatment to people’s attention and 
contribute to an open debate in the HCST field. 
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Further research
Although the level of access to HSCT for pediatric patients with MDS or relapsed 
AML seems to be high, the majority of children with acute leukemia suffer from acute 
lymphoblastic leukemia (ALL). There is a large variety of ALL subtypes and generally 
only the patients diagnosed with high risk ALL types are considered eligible for HSCT. 
However, to decide who to transplant and who not to transplant, and in which time frame 
remains difficult to assess. For patients with ALL there is less consensus on who might 
benefit from HSCT and who might not, compared to MDS and relapsed AML. Some 
physicians, transplant centers and/or hospitals are in favor of HSCT, whereas others are 
reluctant. It would be interesting to see whether this debate influences access to HSCT. 
Furthermore, it remains unknown if there are barriers for receiving HSCT for adult 
patients in the Netherlands and what they might be. This point still deserves our 
attention and discussion with professionals in the HSCT field. It may clarify who are the 
patients with deterioration of the clinical condition during the UD search.
To be able to do both studies we need to overcome a level of resistance and find a way 
to cope with different HSCT centers with different protocols and different attitudes towards 
HSCT. It will be a challenge, but maybe consensus on therapy may help the field forward.
HLA HAPLOTYPES
Analyzing the impact of the patients’ human leukocyte antigens (HLA) haplotypes on 
UD search and HSCT outcome produced several interesting results in chapter 3. We 
used information on frequent HLA haplotypes (FH) with high linkage disequilibrium 
(LD) as a proxy for HLA haplotype matching additional to HLA antigen or allele 
matching between donor and patient. Therefore an uncertainty of actual matching of 
HLA haplotypes between donor and patient exist which may have diluted our results, 
but did not prevent us from finding significant results.
For patients who have 1 or 2 FH a donor is found more often and faster compared to 
patients who have no FH. This holds true for UD searches in both 9/10 HLA mismatched 
and 10/10 HLA matched donor-recipient pairs. Furthermore, in patients who have 1 or 2 
FH and are transplanted with a 10/10 HLA matched donor the cumulative incidence of 
acute graft-versus-host disease (aGVHD) is decreased compared to patients who have 
no FH. Unfortunately for the patient less aGVHD is not translated into less mortality, 
but also not in more relapse.
Biological mechanism
The fact that 10/10 HLA matched donor-recipient pairs who have frequent HLA haplotypes 
encounter less transplantation related complications, in particular the incidence of aGVHD 
implies that there is more to successful HSCT than matching for HLA class I and class II 
genes alone. It confirms and extends evidence that there are non-HLA gene-coding regions 
within the MHC that have a biological important role in transplantation immunology. We 
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7tried to identify which part of the MHC region is most responsible for the beneficial effect 
we see on aGVHD incidence. Patients with FH in highest LD between both HLA-A and -C or 
–B, and HLA-C or -B and -DRB1 had the lowest incidence of aGVHD suggesting that these 
additional genes might be located both telomeric and centromeric to HLA-B.
Onset of aGVHD might not depend on non-HLA gene matching between donor and 
patient, but also on immune regulation possibly affected by the presence of a certain single 
nucleotide polymorphism (SNP) in cytokine encoding genes within the MHC region in either 
patient or donor. However, it remains unknown which genes or which SNPs play a role. 
Clinical implications
It is not possible to influence the patients’ HLA haplotypes, they are either frequent or 
they are not. 
However, the knowledge about the patients’ HLA haplotypes can be used to 
optimize the UD search. Meaning, that it might make sense for those patients with 
FH who have a (large) number of potential 10/10 HLA matched donors available to 
search for a donor ‘close to home’. It implies that the probability of additional matching 
of HLA haplotypes and therefore matching non-HLA polymorphism will be increased, 
improving chances of successful HSCT. 
By transplanting patients with 10/10 HLA matched AND HLA haplotype ‘matched’ 
donors the burden of aGVHD can be decreased; for the patient by improving their quality 
of life (QOL), for the nurses who care for these patients and financially for the whole society.
Further research
Identification of the non-HLA genes in the human MHC which are important in HSCT may 
contribute to a better understanding of the underlying mechanisms leading to aGVHD. 
Immunogenetic profiles for successfully transplanted individuals including parameters 
as HLA haplotypes and cytokine gene polymorphism may help us understand the 
biological mechanism responsible for the beneficial effect of HLA haplotype matching.
AA SEQUENCE AND PHYSICOCHEMICAL PROPERTIES
We describe the development of an algorithm predictive for cytotoxic T cell (CTL) 
alloreactivity in chapter 4. This algorithm is based on the structure of HLA class I 
molecules and the amino acid (AA) positions involved in T cell receptor (TCR) contact or 
peptide binding. Positions 62, 63, 73, 80, 116, 138, 144 and 163 were found to be most 
predictive for the absence of a cellular alloreactive response in vitro (measured by a 
CTLp assay). These positions formed the basis for a weighted AA mismatch score. Donor-
recipient pairs with the highest mismatch scores are estimated to be 13 times more likely 
to have a negative CTLp assay.  Next, in chapter 5 we tested the clinical relevance of 
this weighted AA mismatch score in a HSCT setting. Unfortunately we could not find 
an association between our score and HSCT outcome. Despite the fact that a negative 
CTLp test itself was confirmed to have a beneficial effect on incidence of mortality after 
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HSCT. Finally, in chapter 6 we confirmed the difference between humoral and cellular 
allorecognition in vitro. We tested an algorithm developed for the humoral immune 
response in organ transplantation in the setting of HSCT. The algorithm focuses on 
physicochemical properties of AA differences in the donor and patients’ HLA molecules. 
In humoral allorecognition large physicochemical AA differences more often result in 
antibody responses while in cellular allorecognition large physicochemical AA differences 
more often result in absence of cytotoxic T cell responses. In vivo, the immune responses 
seem to be more similar. For both organ transplantation and HSCT donor-recipient pairs 
having HLA mismatches with small physicochemical AA differences seem to be preferred, 
due to indirect recognition rather than direct T cell allorecognition.
Clinical implications
The reason for conducting this research started with the question: “How to select the 
best donor for our patient?” Even patients transplanted with a 10/10 HLA matched 
donor do not have a guaranteed successful HSCT outcome and, on the other hand, 
some patients transplanted with a single 9/10 HLA mismatched donor will have 
excellent HSCT outcome. To answer this question, we have been looking at matching 
for HLA loci, HLA alleles, AA positions in the HLA molecule and physicochemical 
properties of these AAs. We are now able to correctly predict CTL alloreactivity in vitro, 
but unfortunately we are not able to predict the clinically relevant CTLs correctly. This 
implies that our algorithm is not yet ready to be implemented in donor selection and 
more often alternative options for mismatched unrelated donors need to be used.166
Biological mechanism
Results from research performed in this thesis suggest that AA residues in the α helices have 
different effects on T cell allorecognition compared to AA residues in the β sheet, where the 
nature of the AA appear to be decisive. All AA differences in the α helices seem to be equally 
important in causing alloimmunity via HLA/TCR interaction, while only large AA differences 
(non-compatible for combined physicochemical properties) in the β sheet could influence 
allorecognition. Furthermore, when considering electrostatic (EMS) or hydrophobic (HMS) 
differences of AA alone, positions in the entire α1/α2 domain are important. 
However, it also became clear that the CTLp assay gives a sum of all aspects recognized 
by T cells including recognition of mHags, NIMA/IPA and cross reactivity. It is obvious we 
are not able to predict such a complex reaction by simply looking at the AA sequence 
of the HLA molecules of a donor-recipient pair alone. Furthermore, in a HSCT setting 
the CTLp assay measures the immune response before transplantation, mainly based on 
direct recognition of the mismatched HLA class I antigen and therefore predict absence 
of direct allorecognition. After transplantation the presence of (highly physicochemical 
different) AA differences are more likely to be associated with indirect allorecognition 
and antibody formation causing the discrepancy between in vitro and in vivo results.
Unlike antibodies, TCRs have the property that they only recognize a foreign 
antigen when it is associated with a self HLA molecule. It is possible that a TCR may not 
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7recognize a peptide presented in an HLA molecule which contains a large number of AA 
differences or AA which are physicochemically very different than self HLA molecules. 
This might be the reason why we see opposite associations between HLA molecule 
disparity and allorecognition in humoral and cellular immunity in vitro, reflecting 
mainly direct recognition. However, inside the body the immunogenic responses might 
be more similar due to additional effects of indirect recognition. 
Further research
In our opinion, the limits of epidemiological studies into CTL alloreactivity on a national 
level have been reached. It may be more effective to try to associate the number of AA 
positions directly to HSCT outcome without CTLp assay in a very large homogeneous 
data-set. This will require a strict definition of the study population and collaboration 
within Europe or the USA to reach sufficient numbers. However, the complexity of the HLA 
system may make it impossible to delineate an immunologically sound mechanism from 
patient survival data43. Especially with regard to identifying specific AA positions which 
may be responsible for TCR recognition and or peptide binding. In order to reliably predict 
HSCT outcome, we need to understand the mechanisms involved in T cell recognition and 
regulation causing alloreactivity first. This may involve going back to the lab to test what is 
recognized in a CTLp assay. Ideally, future research would combine both. 
Alternatively, it may be worthwhile to try and combine available algorithms (ours, 
HLAMatchmaker and/or the one from Cambridge) for both cellular and humoral 
alloreactivity to predict (long-term) HSCT outcome.
Furthermore, the upcoming use of CBU alternatively to mismatched unrelated 
donors may provide a whole new interesting research direction in unrelated HSCT.
CONCLUSION
The question whether access to HSCT in the Netherlands is equal for all eligible patients 
remains unknown. However, a specific group of eligible children do have equal access 
to HSCT. Maybe in the future we are able to extend this research to other groups and 
adult patients too.
Knowledge of the patients’ HLA haplotypes can have value in the search for an 
unrelated donor. Furthermore, matching donors and patients for HLA haplotype 
on top of HLA allele matching proved to have an additional beneficial effect on the 
development of aGVHD. Now remains the task to determine which genes in the human 
MHC are responsible for this effect.
Despite the fact that we have made steps in understanding how cellular allorecognition 
might work, we were unable to translate that to the clinical setting. Our research also 
shows that cellular and humoral allorecognition seem to be more similar in vivo and several 
available algorithms may be combined to predict clinical HSCT outcome in the future.
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METHODOLOGICAL STRENGTHS AND CONSIDERATIONS
Study design
The studies described in this thesis are among pediatric patients registered at DCOG, 
patients for whom an unrelated donor search was initiated at Europdonor Foundation, 
and/or patients who underwent a HSCT at LUMC, UMCU or Erasmus MC. The studies 
are all based on a retrospective cohort design. Information on UD search was extracted 
from the patients’ electronic and paper charts at Europdonor Foundation. Clinical and 
HSCT related information were made available by the HOVON Data Center through 
the European group for Blood and Marrow Transplantation (EBMT) patient database. 
By linking these databases for each patient a vast amount of information was available 
to investigate.  All three databases are systematically updated for research purposes. 
Missing data and patients loss to follow-up was minimal.
In order to reach sufficient numbers we included both pediatric and adult patients 
diagnosed and/or transplanted between 1987 and 2008. As a result the study population 
is heterogeneous regarding a number of factors, including age of the patients; year the 
HSCT was performed; type of induction and/or conditioning therapy used; use of T cell 
depletion (TCD) and underlying disease. 
The ideal study design would have been a prospective cohort design and we are 
aware that using a retrospective design may limit inference of causality.167 However, it 
would have taken many years to obtain a large enough patient population to conduct 
a prospective analysis because patients eligible for HSCT suffer from rare diseases. 
Because the field of HSCT is constantly evolving also in a prospective setting it would 
be impossible to control all factors and guarantee a homogeneous study population.
When investigating access to HSCT a retrospective design might even be the 
preferred method, because we can be certain our investigation itself did not introduce 
bias. A prospective study on access to HSCT might unwillingly influence the decision a 
physician will make because he/she knows he/she is being observed.
However, the research described in this thesis might be subject to certain types of 
bias or other considerations may apply. These are discussed in the following paragraphs. 
Potential bias
Bias is any error resulting from methods used by the investigator to recruit individuals 
for the study, from factors affecting the study participants (selection bias) or from 
systematic distortions when collecting information about exposures and diseases 
(information bias). Both types of bias lead to inclusion or exclusion of certain patients 
which may lead to biased outcome and/or conclusions of the analyses.
Patients were selected based on presence of certain information, including eligibility 
for HSCT (access analysis); successful CTLp assay (development of the algorithm); HLA-
haplotypes known from descend (HLA haplotype analysis) and/or complete allele level 
HLA typing (all included patients had known HLA typing). Before collecting the data 
we tried to eliminate selection and information bias as much as possible. Information 
92
7bias may not be a serious problem because ascertainment of disease is considered 
to be very accurate. HSCT is a radical treatment you would not give to a patient if 
the disease would not be certain. Also initial HLA typing of both patient and donor 
is confirmed in a second typing (called confirmatory typing, following World Marrow 
Donor Association (WMDA) standards) to be certain the typing is correct. The study 
cohorts were defined at the time of DNA typing, which was introduced in 1996. Before 
1996 HLA was tested serologically. However, this change in technology most likely did 
not introduce information bias in our datasets because the HLA of all patients and 
donors was typed at the allele level in retrospect. 
In the analysis of access to HSCT we believe selection bias does not play a role. 
Registration at the DCOG is mandatory, therefore we included all pediatric patients 
diagnosed with MDS or relapsed AML. In the haplotype analysis we selected patients 
based on known HLA haplotypes from descent. This may have led to selection of a 
younger population than the general transplanted population because older patients 
more often do not have parents able to be typed for their HLA. However, within the 
selected population age of the patient was not different between the groups of patients 
with no, 1, or 2 frequent HLA haplotypes. For development of the AA mismatch score 
we were dependent on the HLA class I mismatches that were available, which is certainly 
not random. The CTLp assay is not performed for research purposes, but has a clinical 
indication. The mismatches in our dataset determined which AA positions we identified 
in our algorithm to be associated with the CTLp assay. Therefore, if other HLA class I 
mismatches would have been included other AA positions may have been identified.
Confounding
A confounder is a factor which is associated with ‘exposure’ of interest (frequent HLA 
haplotype, AA mismatch score, EMS/HMS) and independently affects the probability 
of a certain outcome (CTLp assay, cumulative incidence of mortality/aGVHD/relapse). 
If the prevalence of these confounding factors is different between groups with and 
without, or different levels of ‘exposure’ of interest, they will distort the observed 
association between outcome and exposure under study if not taken into account. 
As mentioned before, the study population is heterogeneous with respect to all 
kind of covariates; however it is unlikely that our results are explained by confounding 
factors known to be associated with HSCT outcome. Data on all known factors was 
available to us from the EBMT and Europdonor Foundation databases and all statistical 
analyses were based on multivariate models, i.e. adjusted for confounding factors. 
Potential confounding factors were evaluated for each end point separately and 
identified when including them in the model (one by one), the crude association (β 
estimate) changed by >10%. Because of relevance of number of AA differences on 
alloreactivity and HSCT outcome, we decided beforehand to include the total number 
of AA differences in models evaluating AA position and/or physicochemical properties. 
According to our definition of a confounder (i.e. >10% change in crude estimate), 
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several covariates were identified as confounding factor, but the changes in estimates 
were small. We believe we have dealt with possible confounding in the appropriate way, 
so it is unlikely that confounding from known factors has had more than minor effects 
on our risk estimates. However, residual confounding from unknown or unmeasured 
(such as mHags or NIMA) factors might be a problem.
Competing risks analysis
Standard survival analysis is a method to investigate time to event data, estimating the 
cumulative incidence function or the probability of experiencing an event by a given 
time point. Often, a patient may experience an event other than the one of interest 
which alters the probability of experiencing the event of interest. Such events are 
known as competing risk events. Competing risks often occur in HSCT data and they 
need to be taken into account appropriately. Most common example is the competing 
risks of relapse and death in remission. Until recent almost exclusively in medical 
literature the analysis of HSCT outcome was performed using Cox proportional hazards 
models for each event of interest. We believe this model is not adequate because it 
treats the competing events as censored observations, which may lead to misleading 
or biased results.168,169 Since the publication of Fine and Gray in 1999 on their approach 
to competing risks, more and more people in the HSCT field acknowledged the need to 
analyze survival data differently. Therefore, we estimated hazard ratios and corrected 
for competing risks using the proportional hazards model for the subdistribution of 
competing risks of Fine and Gray.116 to quantify associations between the variables 
of interest in this thesis and cumulative incidence of ≥ grade II aGVHD, mortality and 
relapse. We believe this is a major strength of our analyses.
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&ABBREVIATIONS
AA  amino acid
ALL  acute lymphoblastic leukemia
AML  acute myeloid leukemia
APC  antigen presenting cell
ATG  anti-thymocyte globulin
BM  bone marrow
BMDW  bone marrow donors worldwide
CBU  cord blood unit
CMV  cytomegalovirus
CP  chronic phase
CR  complete remission
CTL  cytotoxic T lymphocyte
CTLp  cytotoxic T lymphocyte precursor
D  delta
DCOG  Dutch childhood oncology group
DLI  donor lymphocyte infusion
EBMT  European blood and marrow transplantation 
EM  expectation maximization
EMS  electrostatic mismatch score
Erasmus MC Erasmus medical center
FD  family donor
FH  frequent haplotypes
GF  genotype frequency
GvH  graft versus host
GVHD  graft versus host disease
GVL  graft versus leukemia
HF  haplotype frequency
HLA  human leukocyte antigens
HMS  hydrophobic mismatch score
HR  hazard ratio
HSCT  hematopoietic stem cell transplantation
HvG  host versus graft
JMML  juvenile myelomonocytic leukemia
KIR  killer cell immunoglobulin like receptors
LD  linkage disequilibrium
LMP2/7  low molecular weight protein 2/7
LUMC  Leiden university medical center
MDS  myelodysplastic syndrome
MHC  major histocompatibility complex
Abbreviations
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mHags  minor histocompatibility antigens
MICA/B  MHC class I chain-related gene A (B)
MLC  mixed lymphocyte culture
MPS  myeloproliferative syndromes
Msat  microsatellites
MUD  matched unrelated donor
NMDP  National marrow donor program (USA)
OR  odds ratio
PBL  peripheral blood lymphocyte
PBSC  peripheral blood stem cells
SBT  sequence based typing
PCR-SSP  polymerase chain reaction sequence specific primer
QOL  quality of life
SNP  single nucleotide polymorphism
TAP1/2  transporter associated with antigen processing 1/2
TBI  total body irradiation
TCD  T cell depletion
TCR  T cell receptor
TNF  tumor necrosis factor
TRM  treatment related mortality
UD  unrelated donor
UMCU  university medical center Utrecht
WMDA  World Marrow Donor Association
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&NEDERLANDSE SAMENVATTING
DOEL EN OPZET
De studies beschreven in dit proefschrift zijn gericht op het verbeteren van een aantal 
aspecten van onverwante stamceltransplantatie, zodat in de toekomst mogelijk meer 
patiënten genezen kunnen worden door deze therapie. Het proefschrift omvat drie 
verschillende, maar verwante onderwerpen. Ten eerste kijken we naar de mate van 
toegang tot stamceltransplantatie in Nederland; we zoeken manieren om de zoektocht 
naar een onverwante donor te optimaliseren en proberen acceptabele verschillen 
tussen donor en patiënt te identificeren; als laatste willen we ontdekken hoe we de 
klinische uitkomst na stamceltransplantatie verder kunnen verbeteren.
In hoofdstuk 2 onderzoeken we de toegang tot stamceltransplantatie in Nederland 
voor kinderen met MDS of recidiverende AML. We bekijken of patiënten die in aanmerking 
komen voor een stamceltransplantatie deze ook daadwerkelijk krijgen aangeboden. 
Wanneer een patiënt niet goed doorverwezen is gaan we bekijken wat de redenen 
daarvoor zijn om te zien of deze legitiem waren of niet. Hoofdstuk 3 beschrijft de rol 
die frequente HLA haplotypen kunnen spelen in de zoektocht naar een onverwante 
donor en wat het effect kan zijn op de klinische uitkomst na stamceltransplantatie als 
een patiënt zulke frequente HLA haplotypen heeft. In hoofdstuk 4 stellen we een nieuw 
algoritme voor dat de kans op positieve CTL alloreactiviteit voorspeld voorafgaand aan de 
stamceltransplantatie. Dit algoritme is gebaseerd op de aminozuur sequentie van de HLA 
moleculen die verschillend zijn tussen 131 donor-patiënt combinaties. We kijken naar het 
aantal aminozuur verschillen, de positie van de aminozuren in het molecuul en naar de 
fysicochemische eigenschappen van de aminozuren die verschillend zijn. Dit algoritme kan 
effectief zijn bij het identificeren van acceptabele verschillen tussen donor en patiënt, maar 
voordat het zover is moet het algoritme wel klinisch gevalideerd worden. Daarom proberen 
we het gebruik van dit algoritme te vertalen naar uitkomst na stamceltransplantatie, deze 
studie wordt beschreven in hoofdstuk 5. Ten slotte wordt in hoofdstuk 6 een gelijksoortig 
algoritme getest wat ontwikkeld is door de transplantatie groep in Cambridge. Dit 
algoritme was oorspronkelijk gericht op het voorspellen van humorale alloreactiviteit bij 
orgaantransplantatie. Wij vroegen ons af wat de toegevoegde waarde van dit algoritme 
zou zijn wanneer we kijken naar cellulaire afweer bij stamceltransplantatie.
TOEGANG TOT STAMCELTRANSPLANTATIE
Het opzetten en uitvoeren van een onderzoek om de toegang tot stamceltransplantatie 
in Nederland te onderzoeken voor volwassen patiënten die in aanmerking komen voor 
een stamceltransplantatie bleek een grotere uitdaging dan we op voorhand hadden 
verwacht. Het bepalen van het absolute aantal patiënten die in aanmerking komen 
voor stamceltransplantatie was niet mogelijk, wat te wijten was aan twee factoren. Ten 
eerste is er geen verplichte registratie voor volwassenen in Nederland en ten tweede 
zijn er geen strikte nationale richtlijnen die bepalen welke patiënten in aanmerking 
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komen voor stamceltransplantatie en welke niet. Als gevolg van deze obstakels en een 
zekere mate van weerstand van professionals in het stamceltransplantatie veld hebben 
we besloten om ons onderzoek te richten op kinderen.
Voor kinderen is er een verplichte registratie bij de Stichting Kinderoncologie 
Nederland (SKION) en er zijn nationale behandel protocollen beschikbaar die veel strenger 
worden nageleefd in vergelijking met die voor volwassen. We hebben een populatie 
kinderen geïdentificeerd met MDS en recidiverende AML die in aanmerking kwamen voor 
stamceltransplantatie, waarvan uiteindelijk 95% toegang had tot een stamceltransplantatie. 
In 5% van de gevallen is het twijfelachtig waarom er geen zoektocht naar een onverwante 
donor werd gestart. De meeste kinderen met MDS en recidiverende AML krijgen dus een 
stamceltransplantatie aangeboden en dat is een bemoedigende bevinding.
Klinische toepassing
De limiet voor een aanvaardbaar tijdsinterval tussen diagnose en datum van overlijden/
datum van laatste follow-up die we gebruikt hebben om te bepalen of er een zoektocht 
naar een onverwante donor gestart had moeten worden is willekeurig gekozen. Daarom 
is de 5% die geen toegang hebben tot stamceltransplantatie geen definitief percentage 
en kan dus onderhevig zijn aan discussie afhankelijk van de omstandigheden van elke 
specifieke patiënt. Helaas waren we niet altijd op de hoogte van deze omstandigheden 
en/of de klinische toestand van de patiënten om hierover te kunnen oordelen. Dit had 
wel als gevolg dat we op deze manier objectief naar de data konden kijken en alle 
patiëntgegevens op dezelfde manier hebben behandeld.
Als we onze resultaten vergelijken met de resultaten uit andere landen 
blijkt dat patiënten in Nederland een hoge mate van de toegang hebben tot 
stamceltransplantatie, maar dit geld alleen voor deze specifieke groep van kinderen. 
We kunnen alleen maar speculeren over de redenen hiervoor, maar deze bevindingen 
suggereren het belang van een betrouwbaar registratie systeem en gedetailleerde 
aanbeveling in behandelprotocollen over welke patiënten in aanmerking komen voor 
stamceltransplantatie die landelijk worden opgevolgd.
Anderzijds blijft het ook belangrijk om boven water te krijgen waarom 
stamceltransplantatie in sommige gevallen niet aangeboden wordt als potentiële 
therapie voor patiënten die daarvoor wel in aanmerking komen. Slechte klinische 
toestand van de patiënt kan een belangrijke reden zijn voor een arts om een de 
zoektocht naar een onverwante donor niet te starten. Het is moeilijk om te bepalen 
wat het optimale moment is om over te gaan tot stamceltransplantatie, maar als we 
strikt kijken naar de tijdsintervallen, ongeacht wat er gebeurde met de patiënt op een 
later tijdstip, dan hadden die acht kinderen (5%) toegang moeten hebben gehad tot 
stamceltransplantatie. Dit benadrukt dat vroege verwijzing nog steeds moet worden 
aangemoedigd. Met de publicatie van deze resultaten hopen we de kwestie van gelijke 
toegang tot behandeling onder de aandacht te brengen en om bijdrage te leveren aan 
een open debat in het stamceltransplantatie veld.
&Verder onderzoek
Hoewel het lijkt of er gelijke toegang tot stamceltransplantatie is in Nederland, hebben 
we dit alleen onderzocht in de subgroep kinderen met MDS of een recidief AML. De 
meerderheid van de kinderen met acute leukemie lijden echter aan ALL. Er is een grote 
verscheidenheid aan subtypen ALL en doorgaans zijn enkel de patiënten met een hoog 
risico degene die in aanmerking komen voor stamceltransplantatie. Het blijft moeilijk 
om te beslissen wie wel en niet te transplanteren en in welke tijdspanne. In vergelijking 
met MDS en recidiverende AML is er voor patiënten met ALL minder consensus bereikt 
over wie baat heeft bij een stamceltransplantatie en wie misschien niet. Sommige artsen, 
transplantatie centra en/of ziekenhuizen zijn pro stamceltransplantatie, terwijl anderen 
meer terughoudend zijn. Het zou interessant zijn om te zien of deze ‘controverse’ de 
toegang tot stamceltransplantatie beïnvloedt.
Bovendien blijft onbekend of er belemmeringen zijn voor het ontvangen van 
stamceltransplantatie voor volwassen patiënten in Nederland en wat deze zouden 
kunnen zijn. Dit punt verdient onze aandacht en verdere discussie met professionals in 
het stamceltransplantatie veld. 
Voor beide studies zal een bepaalde mate van weerstand overwonnen moeten 
worden. Bovendien moet een manier gevonden worden om met verschillende 
stamceltransplantatie centra met verschillende protocollen en verschillende houdingen 
ten opzichte van stamceltransplantatie om te gaan. Het zal een uitdaging zijn, maar 
wellicht kan consensus over de behandeling het veld verder helpen.
HLA HAPLOTYPEN
De impact van de HLA haplotypen van de patiënt op de zoektocht naar een onverwante 
donor en stamceltransplantatie uitkomst heeft verscheidene interessante resultaten 
opgeleverd. We gebruikten informatie over frequente HLA haplotypen (FH) met hoge 
linkage disequilibrium (LD) als proxy voor matching van HLA haplotypen bovenop 
matching van HLA loci. Omdat we het HLA haplotype van de donor niet kennen is er een 
mate van onzekerheid of het HLA haplotype daadwerkelijk gematcht is tussen donor en 
patiënt. Dit heeft mogelijk onze resultaten verdund, maar heeft niet voorkomen dat we 
significante resultaten hebben gevonden.
Voor patiënten die 1 of 2 FH hebben wordt vaker en sneller een onverwante donor 
gevonden in vergelijking met patiënten die geen FH hebben. Dit geldt voor 9/10 HLA 
mismatchte en 10/10 HLA identieke donor-patiënt combinaties. Bovendien wordt bij 
patiënten die 1 of 2 FH hebben en getransplanteerd zijn met een 10/10 HLA identieke donor 
minder acute graft-versus-host disease (aGVHD) of omgekeerde afstoting gezien vergeleken 
met patiënten die geen FH hebben. Helaas vertaald deze vermindering van aGVHD zich niet 
in een verbetering van de overleving, maar er komen ook niet meer recidieven voor.
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Biologisch mechanisme
Dat 10/10 HLA identieke donor-patiënt combinaties met FH minder transplantatie 
gerelateerde complicaties ondervinden, voornamelijk een verlaging van aGVHD, 
betekent dat er meer toe bijdraagt aan een succesvolle stamceltransplantatie dan 
alleen matching voor HLA klasse I en klasse II genen. Het bevestigt dat er een gebied 
is binnen het MHC dat niet codeert voor HLA genen dat een biologisch belangrijke rol 
in transplantatie-immunologie heeft. We hebben geprobeerd het deel van het MHC te 
identificeren dat het meest verantwoordelijk was voor dit gunstige effect op aGVHD 
incidentie. Patiënten met FH die een hoge LD tussen zowel HLA-A en-C of-B en HLA-C 
of-B en-DRB1 hebben, hebben het minste aGVHD wat suggereert dat deze extra genen 
zich zowel telomeric als centromeric aan HLA-B bevinden.
Het optreden van minder aGVHD bij donor-patiënt combinaties met FH is mogelijk 
niet alleen afhankelijk van additionele non-HLA gen matching. Immuun regulatie die 
beïnvloedt wordt door de aanwezigheid van een bepaalde nucleotide polymorfisme 
(SNP) in cytokine-coderende genen in het MHC kan hier ook een rol in spelen. Het blijft 
echter onbekend welke genen en/of welke SNPs een rol spelen.
Klinische toepassing
Het is niet mogelijk om de HLA haplotypen van de patiënt te beïnvloeden, ze zijn ofwel 
frequent of niet. Echter, kennis over de HLA haplotypen van de patiënt kan worden 
gebruikt om de zoektocht naar een onverwante donor te optimaliseren. Dit houdt in 
dat het misschien zinvol is voor patiënten met FH die een (groot) aantal potentiële 
10/10 HLA gematchte donoren beschikbaar hebben te zoeken naar een donor ‘dicht 
bij huis’. De kans op matching van de HLA haplotypen en dus de kans op matching van 
andere polymorfismen in het MHC zal daardoor toenemen, wat mogelijk resulteert in 
een grotere kans van slagen van de stamceltransplantatie.
Door patiënten te transplanteren met een donor die 10/10 HLA gematcht EN een 
HLA haplotype gematcht is kan de ‘last’ van aGVHD worden verminderd. De kwaliteit 
van leven van de patiënt wordt verbeterd, de werkdruk voor de verpleegkundigen 
die voor deze patiënten zorgen wordt verminderd en de financiële last voor de hele 
samenleving zal afnemen.
Verder onderzoek
Identificatie van de non-HLA genen in het MHC die belangrijk zijn voor stamceltransplantatie 
kan bijdragen tot een beter begrip van de onderliggende mechanismen die leiden tot 
aGVHD. Het opstellen van immunogenetische profielen voor donor-patiënt combinaties 
die met succes getransplanteerd zijn kan ons helpen begrijpen welke polymorfismen 
verantwoordelijk zijn voor het gunstige effect van HLA haplotype matching. 
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&AMINOZUUR SEQUENTIE EN FYSICOCHEMISCHE EIGENSCHAPPEN
We beschrijven de ontwikkeling van een algoritme die CTL alloreactiviteit voorspeld. Dit 
algoritme is gebaseerd op de structuur van HLA klasse I moleculen en AA posities die T 
cel receptor (TCR) contact of peptide binding beïnvloeden. Posities 62, 63, 73, 80, 116, 138, 
144 en 163 bleken het meest voorspellend te zijn voor de afwezigheid van een cellulaire 
alloreactieve respons in vitro (gemeten met een CTLp assay). Deze posities vormden 
de basis voor een gewogen AA mismatch score. Donor-ontvanger combinaties met de 
hoogste mismatch score hebben 13 keer meer kans op een negatieve CTLp test. Vervolgens 
onderzochten we de klinische relevantie van deze gewogen AA mismatch score in een 
stamceltransplantatie setting. Helaas konden we geen verband vinden tussen onze score 
en stamceltransplantatie uitkomst. Ondanks het feit dat een negatieve CTLp test zelf wel 
een gunstig effect op overleving na stamceltransplantatie heeft. Ten slotte hebben we 
bevestigd dat er een verschil bestaat tussen humorale en cellulaire alloreactiviteit in vitro. 
We hebben het algoritme wat ontwikkeld was om humorale immuunrespons te voorspellen 
in orgaantransplantatie in een stamceltransplantatie setting getest. Dit algoritme is 
gericht op fysicochemische verschillen van aminozuren in een HLA klasse I molecuul. 
In orgaantransplantatie resulteren grote fysicochemische AA verschillen vaker in een 
antilichaamrespons terwijl in stamceltransplantatie grote fysicochemische AA verschillen 
vaker de afwezigheid van een CTL respons voorspeld. In vivo is de immuunrespons 
meer vergelijkbaar. Zowel in orgaantransplantatie als in stamceltransplantatie lijken HLA 
mismatches met kleine fysicochemische verschillen de voorkeur te hebben.
Klinische toepassing
De reden voor het uitvoeren van dit onderzoek begon met de vraag: “Hoe kan ik de 
beste donor voor mijn patiënt kiezen?” Zelfs patiënten die getransplanteerd worden 
met een 10/10 HLA identieke donor hebben geen garantie op een succesvolle uitkomst 
van de stamceltransplantatie. Anderzijds, een patiënt die getransplanteerd wordt met 
een 9/10 HLA mismatchte donor kan een uitstekende stamceltransplantatie uitkomst 
hebben. Om deze vraag te beantwoorden, hebben we gekeken naar matching voor HLA 
loci, HLA-allelen, AA posities in het HLA-molecuul en de fysicochemische eigenschappen 
van deze AAs. We zijn nu in staat om CTL alloreactiviteit correct te voorspellen in vitro, 
maar helaas zijn we nog niet in staat om de klinisch relevante CTLs correct te kunnen 
voorspellen. Dit houdt in dat ons algoritme nog niet klaar is om te worden toegepast in 
de kliniek voor de selectie van donoren. Vaker zal er uitgeweken moeten worden naar 
alternatieve opties voor mismatchte onverwante donoren zoals navelstrengbloed.
Biologisch mechanisme
Resultaten van onderzoek beschreven in dit proefschrift suggereren dat AA posities in de 
α helices een ander effecten op CTL alloreactiviteit hebben vergeleken met AA posities 
in de β sheet, waar de fysicochemische aard van de AA doorslaggevend is. Alle AA 
verschillen in de α helices lijken even belangrijk bij het veroorzaken van alloimmuniteit 
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via HLA/TCR interactie, terwijl slechts grote AA verschillen (niet-compatibel voor 
gecombineerde fysicochemische eigenschappen) in de β sheet alloimmuniteit kunnen 
beïnvloeden. Als we dan specifiek kijken naar elektrostatische (EMS) of hydrofobe 
(HMS) verschillen van AA zijn alle posities in het gehele α1/α2 domein even belangrijk.
Maar het werd ook duidelijk dat de uitkomst van de CTLp test bepaald wordt door 
een som van factoren die herkend worden door T-cellen. Waaronder ook herkenning 
van mHags, NIMA/IPA en kruisreactiviteit. Het is duidelijk dat we niet in staat zijn om 
een dergelijk complexe reactie te voorspellen door simpelweg naar de AA sequentie 
van het HLA molecuul te kijken. Bovendien meet de CTLp test de immuunrespons 
vóór de transplantatie en is voornamelijk gebaseerd op directe T cel herkenning. Na 
transplantatie kunnen de aanwezigheid van (sterk fysicochemisch verschillende) AA 
verschillen worden geassocieerd met indirecte T cel herkenning en antilichaamvorming 
waardoor het verschil tussen in vitro en in vivo resultaten wellicht verklaard kan worden.
Anders dan antilichamen hebben TCRs de eigenschap dat zij slechts een vreemd 
antigeen herkennen wanneer deze wordt gepresenteerd in een eigen HLA-molecuul. 
Het is mogelijk dat een TCR een peptide niet herkent wanneer het gepresenteerd wordt 
in een HLA-molecuul dat heel anders is dan het eigen HLA molecuul. Dit kan de reden 
zijn waarom wij tegenovergestelde associaties vinden tussen humorale en cellulaire 
immuniteit in vitro, wat voornamelijk een weerspiegeling is van directe herkenning. 
Terwijl in het lichaam de immunogene respons wellicht meer vergelijkbaar is door 
additionele effecten van indirecte herkenning.
Verder onderzoek
De grenzen van epidemiologische studies naar CTL alloreactiviteit op nationaal niveau 
is bereikt. Het is effectiever om te proberen het aantal AA posities direct te koppelen 
aan klinische uitkomst na stamceltransplantatie zonder de CTLp test. Een grote 
homogene dataset is dan vereist, waardoor de onderzoekspopulatie strikt gedefinieerd 
dient te worden en samenwerking binnen Europa of de Verenigde Staten nodig is om 
voldoende aantallen te bereiken. Echter, de complexiteit van het HLA-systeem maakt 
het vrijwel onmogelijk om een immunologisch mechanisme uit patiëntoverleving data 
te extraheren. Vooral met betrekking tot het identificeren van specifieke AA posities die 
verantwoordelijk kunnen zijn voor TCR herkenning en/of peptide binding. Met het oog 
op een betrouwbare manier stamceltransplantatie uitkomst te voorspellen, moeten we 
de mechanismen die betrokken zijn bij T-cel herkenning eerst beter begrijpen. Dit kan 
betekenen dat we terug moeten gaan naar het lab om te testen wat er precies wordt 
herkend in een CTLp test. Idealiter zou toekomstig onderzoek een combinatie van 
beide aanpakken beslaan.
Alternatief kan het nuttig zijn om te proberen een combinatie van beschikbare 
algoritmen (die van ons, HLAMatchmaker en/of die van Cambridge) voor zowel 
cellulaire als humorale alloreactiviteit te maken.
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&Bovendien kan het gebruik van navelstrengbloed als opkomend alternatief voor 
mismatcht onverwante donoren een nieuwe en interessante onderzoeksrichting binnen 
stamceltransplantatie zijn op het gebied van CTL alloreactiviteit.
CONCLUSIE
De vraag of toegang tot stamceltransplantatie in Nederland gelijk is voor alle patiënten 
die hiervoor in aanmerking komen blijft onbekend. Echter, een specifieke groep 
kinderen hebben gelijke toegang tot stamceltransplantatie. Misschien zullen we in de 
toekomst in staat zijn om dit onderzoek uit te breiden naar andere groepen kinderen 
en volwassen patiënten.
Kennis van de HLA haplotypen van patiënten kan van waarde zijn in de zoektocht 
naar een onverwante donor. Bovendien blijkt dat wanneer de HLA haplotypen van 
donor en patiënt overeenkomen dit de ontwikkeling van aGVHD verminderd. Nu rest 
de taak te bepalen welke genen in het MHC verantwoordelijk zijn voor dit effect.
Ondanks het feit dat we stappen hebben gemaakt om te begrijpen hoe cellulaire 
alloreactiviteit zou kunnen werken, waren we niet in staat om dat te vertalen naar 
de klinische setting. Ons onderzoek toont daarnaast aan dat cellulaire en humorale 
alloreactiviteit wellicht meer op elkaar lijken in vivo en dat verschillende beschikbare 
algoritmen gecombineerd dienen te worden om in de toekomst klinische uitkomst na 
stamceltransplantatie te kunnen voorspellen. 
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Immunohematologie en Bloedtransfusie in het LUMC, onder leiding van Prof. Dr. Frans 
Claas en Dr. Machteld Oudshoorn. Sinds december 2012 is ze werkzaam bij de WMDA 
waar ze werkt aan de database voor de annual questionnaire. Voor 2013 staat niet 
alleen de promotie op de planning maar ook een wereldreis.
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